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ABSTRACT
We have identified the genes responsible for SERCA2a-induced reversal of heart failure, the
leading cause of morbidity and mortality in the United States and developed countries.
We have previously shown that restoration of a key enzyme that controls intracellular Ca2
handling, the Sarcoplasmic Reticulum Ca2 ATPase (SERCA2a), induces reversal of heart
failure in humans and experimental models. We used high-density oligonucleotide arrays to
explore the genetic reprogramming responsible for the reversal of heart failure upon adenoviral
gene transfer of SERCA2a in a rat model of pressure overload hypertrophy in transition to heart
failure. We combined model- and data-driven approaches to analyze the resulting multivariate
microarray expression dataset corresponding to 4237 transcript sequences in six experimental
groups. A multiscale systems approach was used that incorporated the main mechanisms
underlying the control of gene expression at the transcriptional level, and the pathologic
compensatory responses that occur in heart failure. The combinatorial control of gene expression
that is thought to occur in mammals was implemented in a signal-processing model at the level
of the heart cell nucleus; it identified 473 SERCA2a regulated genes. The integration of the main
mechanisms underlying the pathologic compensatory responses that take place in heart failure
was fundamental to the discovery of 10 functional transcriptional classes within this group of
genes. In addition, 226 genes that were not targets of SERCA2a but were natural adaptive
responses to aortic banding needed for clinical non-failure, were identified and functionally
categorized. Biological functional distribution of SERCA2a targets revealed that SERCA2a
activates genes that function mainly in the cytoskeleton, ECM, Ca2+ signaling, signal
transduction, cell cycle and growth and development pathways. The integration of model- and
data-driven ideas was crucial to the elucidation of specific patterns in the multivariate data and
allowed the discovery of novel genes and their potential role in the normalization of multiple
pathways within the failing cell. This is a novel, powerful and portable method to elucidate
multivariate genome-wide transcriptional networks from primary microarray data.
Thesis Supervisor: David E. Housman
Title: Ludwig Professor of Biology
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The real act of discovery consists not in finding new lands but seeing with new eyes.
Marcel Proust
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I Introduction
Heart Failure is the leading cause of morbidity and mortality in developed countries (1). Once
heart failure becomes symptomatic, the 5 year survival is less than 50% , a prognosis worst than
most malignancies (1). The only curative treatment available is heart transplant.
Current attempts to analyze large genomic and proteomic data sets have significant limitations:
(1) Most analyses focus only on the data generated by a system: they are data-driven as opposed
to being model-driven.
(2) Most analyses are not multivariate in nature or do not take into account the multivariate
nature of the data at the price of large approximations which can introduce highly significant
error into the analysis. There are no satisfactory described methods to analyze large multivariate
genomic data sets.
(3) Most functional gene expression analyses lead to the segregation of samples into two groups
(e.g. good prognosis vs. bad prognosis): analytical constructs segregating data in this manner are
often poor approximation of biological complexity.
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We have previously shown that restoration of a key enzyme that controls intracellular Ca2+
handling, the sarcoplasmic reticulum Ca2+ ATPase (SERCA2a), induces functional improvement
and has a protective effect on cardiomyocyte metabolism and intracellular pathways of
hypertrophy and failure in human and experimental models (2). SERCA2a expression has been
shown previously to be down-regulated during heart failure, and restored back to its levels in
healthy hearts by adenoviral gene transfer (3, 4).
The neurohumoral-hemodynamic defense reactions and the hypertrophic reaction in heart failure
exhibit two distinct phases on a time scale: If these reactions are sustained in time, the outcome
will be adaptive on the short-term but maladaptive on the long-term. SERCA2a induces a long-
term adapative response in the failing heart.
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Goals of the study:
To guide new therapeutic modalities for reversing heart failure, study design was aimed at
furthering our understanding of the molecular events that underlie the pathophysiology of heart
failure and its reversal by SERCA2a.
In this model, the insult that leads to heart failure is aortic banding. There are two categories of
responses to aortic banding: natural responses (in the absence of gene transfer), and SERCA2a-
induced responses. Natural responses can be adaptive or maladaptive. When SERCA2a is
introduced into banded failing hearts, it elicits adaptive responses since it brings clinical non-
failure.
At the most basic level, we wanted to know which molecular responses to aortic banding are
causing failure, and which ones are causing non-failure. Starting from a failing heart or going all
the way back to a non-failing heart, we defined the minimal genetic reprogramming required to
have non-failure in the face of aortic banding.
There are two categories of responses to aortic banding that are needed to have clinical non-
failure: SERCA2a-induced responses (those are the molecular differences that cause the clinical
transition from a failing to a non-failing clinical phenotype, upon SERCA2a infection of failing
hearts), and natural adaptive responses needed for non-failure (those are the genes that have a
stable expression in failure and SERCA2a-induced non-failure, yet are responses to aortic
banding). We identified these functional categories of reprogrammed genes (Fig 1).
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We used oligonucleotide microarrays to characterize gene expression patterns in six
experimental groups (see Materials and Methods). 87 rats were initially divided into two groups:
45 animals had an aortic band placed while 42 were sham-operated. Cardiac adenoviral gene
transfer was performed after development of left ventricular (LV) dilatation in the aortic-banded
animals. In both groups, animals either received gene transfer with Ad.SERCA2a or Ad.Bgal-
GFP or did not undergo gene transfer. They make up the six experimental groups NF, NFV,
NFS, F, FV, and FS (Fig 2).
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II Materials and Methods
Construction of Recombinant Adenoviruses
To construct the adenovirus containing SERCA2a cDNA, we used the method described
by He et al (5), whereby the backbone vector, containing most of the adenoviral genome (pAd.
EASY1) is used and the recombination is performed in Escherichia coli. SERCA2a cDNA was
subcloned into the adenoviral shuttle vector (pAd.TRACK), which uses the cytomegalovirus
(CMV) long terminal repeat as a promoter. The shuttle vector used also has a concomitant green
fluorescent protein (GFP) under the control of a separate CMV promoter. An adenovirus
containing both B-galactosidase and GFP controlled by separate CMV promoters (Ad.Bgal-GFP)
was used as control. The adenoviruses were propagated in 293 cells. The titers of stocks used for
these studies measured by plaque assays were 3x10 1 pfu/mL for Ad.Bgal-GFP and 1.8x10"
pfu/mL for Ad.SERCA2a, with particle/pfu ratios of 8:1 and 18:1, respectively. These
recombinant adenoviruses were tested for the absence of wild-type virus by polymerase chain
reaction (PCR) of the early transcriptional unit El.
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Experimental Protocol
Four-week-old Sprague-Dawley rats (Charles River, Mass; 70 to 80 g) were anesthetized
with pentobarbital (60 mg/kg IP) and placed on a ventilator. A suprasternal incision was made,
exposing the aortic root, and a tantalum clip with an internal diameter of 0.58 mm (Weck, Inc)
was placed on the ascending aorta (6). Animals in the sham group underwent a similar procedure
without insertion of a clip. The supraclavicular incision was then closed, and the rats were
transferred back to their cages.
The animals were initially divided into 2 groups: 1 group of 45 animals with aortic
banding and a second group of 42 animals that were sham-operated. Three animals in the aortic
banding group did not survive the initial operation, and 2 animals in the sham-operated group did
not survive. In the aortic-banded animals, we waited 26 to 28 weeks for the animals to develop
left ventricular (LV) dilatation before cardiac gene transfer. In this banded group as well as in the
sham-operated group, 14 animals did not undergo gene transfer and were followed
longitudinally. The rest of the animals (28 and 26) underwent adenoviral gene transfer with
either Ad.SERCA2a (14) or Ad.Bgal-GFP (12). Figure 2 illustrates the six experimental groups
in the study: NF (Non-Failing), heart with no aortic banding and no gene transfer; NFV (Non-
Failing Virus), no aortic banding but transfer of viral construct (Ad.Bgal-GFP); NFS (Non-
Failing SERCA2a), no aortic banding but transfer of SERCA2a construct (Ad.SERCA2a); F
(Failing), aortic banding but no gene transfer; FV (Failing Virus), aortic banding and transfer of
viral construct; FS (Failing SERCA2a), aortic banding and transfer of SERCA2a construct.
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Adenoviral Delivery Protocol
The group of animals subjected to aortic banding was further subdivided into 3 groups of
14, 14, and 14 receiving Ad.SERCA2a, Ad.Bgal-GFP, or no adenovirus, respectively. The group
of sham-operated animals was also subdivided into 3 groups of 14, 12, and 14 receiving
Ad.SERCA2a, Ad.Bgal-GFP, or no adenovirus. The adenoviral delivery system has been
described previously by our group in detail(7, 8). Briefly, after the rats had been anesthetized and
a thoracotomy performed, a 24-gauge catheter was advanced from the apex of the LV to the
aortic root. The aorta and main pulmonary artery were clamped for 40 seconds distal to the site
of the catheter, and 0.5 ml of adenosine to temporarily slow the heart rate was infused followed
by 200 ml of adenoviral solution (1010 pfu); the chest was then closed, and the animals were
allowed to recover. The antibiotic Cefazolin 20 mg/100 g was injected im as well as
Buprenorphine 0.01 mg/100 g for 2 days to alleviate pain.
Serial Echocardiographic Assessment
After 18 weeks of banding, serial echocardiograms were performed weekly in lightly
anesthetized animals (pentobarbital 40 mg/kg IP). Transthoracic M-mode and 2D
echocardiography was performed with a Hewlett-Packard Sonos 5500 imaging system with a 12-
MHz broadband transducer. A mid-papillary level LV short-axis view was used, and
measurements of posterior wall thickness, LV diastolic dimension, and fractional shortening
were collected. Gene transfer was performed in all animals within 3 days of detection of a drop
in fractional shortening of >25% as compared with the fractional shortening at 18 weeks after
banding. In the sham-operated rats, gene delivery was performed at 27 weeks.
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Characterization of Animals
After 24 weeks of aortic banding, the animals showed echocardiographic signs of LV
hypertrophy, including an increase in wall thickness, both posterior (30%) and septal (25%), a
decrease in LV dimensions (LVEDD 7.5%, LEESD 15%), and an increase in fractional
shortening (4%). After 26 to 27 weeks of banding, these animals had uniformly: 1) small
pericardial effusions, 2) pleural effusions, 3) an increase in lung weight, 4) ascites, and 5)
dyspnea at rest, all indicative signs of severe heart failure. Echocardiographically, LV end-
diastolic dimensions increased (LVEDD 8.7%, LVESD 15.4) and fractional shortening
decreased by 14.3%. Heart weight was increased from 1.6+0.18 to 2.3±0.22 g (p<0.01) in Failing
versus control animals. Heart weight to body weight ratio was increased from 0.27+0.03 to
0.49+0.06 (p<0.004). The overexpression of SERCA2a reduced the heart weight to body weight
ratio to 0.37±0.01 (p<0.00 3 compared to FV, and p<0.002 compared to F).
Immunoblotting
The lysates were prepared at 4'C in a lysis buffer containing (in mmol/L) NaCl 150,
MgCl 2 1, and CaCl2 1, plus detergents and proteinase inhibitors (pH 7.4). The tissue was
homogenized and spun at 1400 rpm (Eppendorf) for 30 minutes. The supernatant was then
filtered through 4 layers of gauze and centrifuged at 15.000 rpm for 60 minutes (Eppendorf).
SDS-PAGE was performed on the supernatant under reducing conditions on 7.5% separation
gels with a 4% stacking gel in a Miniprotean II cell (Biorad). For immunoreaction, the blots were
incubated with 1:1000 diluted monoclonal antibodies to SERCA2a (MA3-919; Affinity
BioReagents), phospholamban (Badrilla), or 1:1000 diluted anti-calsequestrin (MA3-913;
Affinity Bioreagents) for 90 minutes at room temperature. Protein levels of SERCA2a were
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decreased in failing compared to sham left ventricular tissue. Adenoviral gene transfer of
SERCA2a in failing hearts increased SERCA2a protein expression, restoring it to levels
observed in the non-failing hearts. Calsequestrin protein levels did not change among the
different groups, nor did phospholamban.
Validation of microarray data by Quantitative Reverse Transcriptase PCR (QRT-PCR)
Total RNA was isolated and purified from the rat hearts as described below. Following
purification, RNA was quantified using the Agilent Bioanalyzer according to the manufacturer's
instructions. RNA (15 tg) was treated (10 min at 20 C) with amplification grade DNase
I (Promega; Madison, WI) following which the DNase I was heat-inactivated (15 min at 65'C).
QRT-PCR was performed in duplicate using the Qiagen Quantitect RT-PCR kit containing
SYBR Green I (1:30,000, Sigma), forward and reverse primers (50 nM each), and sample RNA
(<500 ng). Accumulation of PCR product was monitored in real time (ABI Prism 7000, Applied
Biosystems), and the crossing threshold (Ct) was determined using the Prism 7000 software. For
each set of primers, a no reverse amplification control was included. Post-amplification
dissociation curves demonstrated the presence of a single amplification product in the absence of
DNA contamination for each set of primers. Fold changes in gene expression were determined
using the ACt method with normalization to total RNA using S18 ribosomal RNA as an internal
control (9).
Microarray Procedures
Total RNA was extracted from rat hearts in each experimental sample using TRIzol
(Invitrogen) according to the manufacturer's recommendations. RNA was resuspended in diethyl
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pyrocarbonate-treated H20 and further purified using the Qiagen (Chatsworth, CA) RNeasy total
RNA isolation kit. RNA was quantified and was used to generate cDNA using the Superscript
Choice system (Invitrogen) according to the Affymetrix protocol (Affymetrix, Santa Clara, CA).
Resulting cDNA was used to generate biotin-labeled cRNA using the ENZO Bioarray High
Yield transcript labeling kit (Affymetrix). cRNA (20 ptg) was fragmented in fragmentation buffer
[40 mM Tris (pH 8.1), 100 mM potassium acetate, 30 mM magnesium acetate] for 35 min at
94 'C. The quality of the cRNA was checked by hybridization to Test3 arrays (Affymetrix).
Subsequently samples were hybridized to rat mU34A oligonucleotide microarrays (Affymetrix),
and staining and scanning according to Affymetrix protocols identified bound sequences.
Oligonucleotide microarray analysis of gene expression was done essentially as described
(Affymetrix). The 8800 oligonucleotide clones on the Affymetrix mU34A microarray are
available from Affymetrix. Images of hybridized microarrays were obtained using a GeneArray
2500 microarray scanner (Affymetrix). Images were analyzed with Affymetrix@ Microarray
Suite software, and intensity data (along with multiple quality control parameters; see
Affymetrix@ Microarray Suite manual) was stored in a database. The software evaluated the
relative level of expression of each transcript represented on the array and labeled it as either
present, absent, or marginal. To this end it combined the results from match/mismatch probe
pairs that interrogate different fragments of a transcript. Probe pair intensities are used as input,
and allow the quantitation and subtraction of signals caused by non-specific cross-hybridization.
The statistical significance of each detection call was indicated by an associated p-value. Single
spots and areas of the array with obvious imperfections were flagged and excluded from
subsequent analyses. Clones that consistently behaved poorly across arrays were excluded from
all analyses. To enable comparison between experiments, intensity data was calibrated
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independently for each array by globally scaling and normalizing the intensities to an average
intensity of 1,500. A minimum value of 150 was assigned to all average differences (AvDiffs)
with an intensity measurement below 150.
Data analysis
4,237 out of the 8,800 array elements were identified as 'present' in at least 2 out of the
10 experimental samples and were used for further analysis. The intensity values were stored in a
table (rows, individual genes; columns, single mRNA samples). Where the same experimental
group had been analyzed on multiple arrays, multiple observations for an array element for a
single experimental group were averaged. An algorithm was developed by our group that
implemented the signal-processing model presented in the text and addressed the goals of the
study. The dataset containing 4,237 array elements was used as the input data. The algorithm
extracted SERCA2a targets in the failing heart, and clustered those genes into functionally
distinct transcriptional profiles. It also extracted the genes that are part of natural adaptive
responses against aortic banding that are needed for clinical non-failure and clustered them into
distinct transcriptional profiles. We calculated intensity ratios between different experimental
samples and a reference sample. The intensity ratio calculated for each gene reflects the relative
abundance of mRNA in the experimental sample versus a reference sample. The use of a
common reference microarray allows the comparison of the relative expression level of each
gene across all the experimental samples (arrays) (10). A 1.2 cutoff value for the ratios was used
(thus the upper cutoff value is 1.2 and the lower cutoff value is 1/1.2 = 0.83). To display the
output graphically as clustered expression data for Figures 5 and 6, the output of the algorithm
was fed into the program Cluster (M. Eisen; http://rana.lbl.gov/EisenSoftware.htm) (10). Genes
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were normalized and mean-centered, then hierarchical clustering was applied to the genes axis
using the unweighted pair-group method with complete linkage as implemented in Cluster. The
distance matrix used was Uncentered Pearson correlation (it is a slight variant of Pearson
correlation; see Cluster manual available at http://rana.lbl.gov/manuals/ClusterTreeView.pdf for
computational details). The results were visualized with Tree View (M. Eisen;
http://rana.lbl.gov/EisenSoftware.htm) (10). All datasets used to generate Figs 5, 6 are included
in Tables 1 and 2.
Statistical analysis
All values were calculated as mean±SD. For the echocardiography data, when the
variables were examined at various intervals, ANOVA with repeated measures was performed.
Statistical significance was accepted at the level of P<0.05.
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III Results
What genes does SERCA2a target in the failing heart?
We initially focused on identifying the genes that are causal for the clinical transition from a
failing to a non-failing clinical phenotype, upon the introduction of SERCA2a into a failing
heart. Starting from a failing heart, the minimal genetic reprogramming required to have non-
failure in the face of aortic banding (keeping other genes unchanged), defines the genes affected
by SERCA2a. A key element in the analysis is the evaluation of the contribution of the gene
delivery system to the gene expression changes which occur in the model system. Previously, we
demonstrated that the clinical transition from failure to non-failure is only due to SERCA2a
expression, and that other elements that are part of the gene expression construct do not
contribute to the clinical transition (7, 11-13). Our goal in this analysis was to substract the
effects of these elements on gene expression profiles in order to identify those gene expression
changes which specifically were contributory to the ability of SERCA2a expression to prevent
heart failure.
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Isolating the genes that are targets of SERCA2a:
In analyzing the data, we relied on the current understanding of mammalian regulation of gene
expression at the transcriptional level(14, 15). The pattern of gene expression in a cell is the
result of a complex molecular computation that the intracellular gene control network performs
in response to information from inside and outside the cell. Gene expression is thought to be
regulated by combinatorial control. Gene regulatory proteins bind to regulatory sequences in the
gene control region. The promoter will integrate activator and repressor signals from this
combination of inputs, and then make a decision to turn the gene ON or OFF, like a genetic
switch, a digital response. The amount of RNA produced, however, varies, and so RNA
abundance is an analogue response, and depends on the strength of the activation signal.
We built a signal-processing model that implements the combinatorial control of gene
expression. In this model, the heart cell integrates inputs (aortic banding at time 1 and gene
transfer at time 2) to change its gene expression and molecular phenotype, leading to a change in
clinical phenotype (outputs) (Fig 2). The myocyte background on which the inputs are added is
the non-failing heart cell. The different inputs will lead to different combinations of signals that
will affect the expression of a gene.
We built a vectorial representation of this input-output system in order to assign cause to a
specific input or combination of inputs when there is a change in expression of a gene (Fig 3).
We wanted to isolate genes that are targets of SERCA2a. Each vector represents the molecular
signals (gene regulatory proteins) transduced for that input at the level of the cell, that
collectively either activate or repress transciption of a gene. The vectors are one dimensional,
have a direction and magnitude. Therefore each vector encodes 2 bits of information. The
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activity of the gene regulatory proteins is determined by the magnitude of the vector. The model
is additive; we ignored synergistic/cooperative effects that might take place when multiple
signals interact to control gene expression. The expression level of a gene (output) is the sum of
the vectorial inputs that converge on the promoter for that gene. The stochastic vector was added
to account for background stochastic fluctuations in gene expression levels. The stochastic vector
is a measure of randomness within the system.
Thus, for a gene across the experimental samples, the input-output system can be described by a
system of 3 linear equations with 7 unknowns:
[1]:NF+AoB+Stoch=F
[2]: NF + AoB + V + GFP + BGal + Stoch = FV
[3]: NF + AoB + V + GFP + SERCA + Stoch = FS
For each gene, we wanted to know which inputs were contributing to the gene expression levels
observed, to identify contributions due to SERCA2a. We can reduce the system of equations to 3
linear equations with 4 unknowns:
[2] -[1]: V + GFP + BGal = FV - F
[3]- [2]: SERCA - BGal = FS - FV
[3]-[1]: V + GFP+SERCA = FS - F
When we perform a two by two comparison of the gene expression levels, F, FV, and FS, as
dictated by the right hand side of the above equations, we get a total of 33 = 27 (F, FV, FS)
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configurations, only 13 of which are possible in real space (only in those 13 does the system of 3
equations have a solution) (Fig 4). These configurations correspond to the global geometric
structures of gene expression levels for a gene. Genes within a configuration are controlled by
the same inputs.
Because there are more unknowns than there are descriptions of the system, for each
configuration, instead of trying to solve these equations, we analyzed all possible solutions to
these equations at once. We considered all the possible combinations of inputs that can lead to
the specific observed outputs. We then chose the most parsimonious solution (16). When gene
expression was found to be affected by SERCA2a, that gene was identified as a target of
SERCA2a (Fig 4).
To assess the robustness of our analytical methodology, we identified SERCA2a targets by an
additional method. Whereas in the combinatorial control model SERCA2a targets were identified
by examining myocytes at the molecular level, here we correlated the molecular phenotype of
myocytes with their clinical phenotype. The molecular phenotype at the level of the heart cell
determines the clinical phenotype at the level of the cardiovascular system. In a cause-effect
sequence, change explains change. The clinical phenotype difference between different
experimental samples is caused by an underlying molecular phenotype difference. Therefore
some of the genes whose expression changes between the two clinical phenotypes are the cause
of the clinical phenotype transition from failure to non-failure. The experimental samples F and
FV belong to the failing clinical category, while FS belongs to the non-failing clinical category.
Here we identified through the use of a molecular-clinical correlation analysis the genes that are
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causal for the clinical phenotype transition. Since SERCA2a is the cause for the clinical
phenotype transition, those genes would be targets of SERCA2a.
The 13 possible gene expression configurations (F, FV, FS) for a gene (Fig 4) were obtained
above by a pairwise comparison of the gene expression levels in F, FV and FS. Each
configuration is thus defined by 3 pairs (for example in Fig 4, configuration 1, FV>F, FS>FV,
and FS>F). We analyzed individual configurations: Where in each pair, a difference at the
molecular level produced a difference a the clinical level, and a similarity at the molecular level
produced a similarity at the clinical level, a triple correlation was recorded, and the gene was
assigned the highest probability of being causal for the clinical transition from failure to non-
failure (a triple correlation is recorded when the gene expression level in F is the same as in FV
[same gene expression levels correlates with same clinical phenotype], F is different from FS,
and FV is different from FS [different gene expression levels correlates with different clinical
phenotypes]; it corresponds to configurations 11 and 13 in Fig 4). Such a gene would have the
highest probability of being a target of SERCA2a. Lower correlation scores (correlation in 2
pairs only, one pair only, or no correlation) were assigned progressively lower probabilities.
Each configuration in Fig 4 was analyzed individually and a correlation score assigned to it (see
Fig 4).
There was agreement between the two methodologies for the identification of SERCA2a targets.
To increase accuracy, we combined the results from both analyses into a composite probability
score describing the likelihood that a gene is a SERCA2a target. All potential SERCA2a targets
(i.e. probability> 0) had a gene expression level in FS different from FV, and in FS different
from F.
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Transcriptional profiling of SERCA2a targets in the failing heart:
The transcriptional reprogramming induced by SERCA2a increased survival to aortic banding as
compared to gene expression levels in NF and F.
Since SERCA2a is decreased in failure and restored back to normal levels in non-failure, we
reasoned that one functional category of SERCA2a targets might be proteins that were brought
back to non-failing levels upon SERCA2a infection (Fig 5, profiles 5, 6). However, if keeping
the transcriptome-proteome state of the normal cell was the most adaptive alternative against
aortic banding, then the cells would not have changed their expression profile from normal.
Therefore, there must be other beneficial responses caused by SERCA2a other than just
normalizing cellular proteins.
SERCA2a acts on a basis of already established natural adaptive and maladaptive responses to
aortic banding. Natural maladaptive responses will be reversed by SERCA2a, while natural
adaptive responses are either optimized or unchanged. In addition, SERCA2a will introduce new
adaptive responses to aortic banding. We isolated these functional categories of reprogrammed
genes.
Transcriptional profiling of SERCA2a targets defined ten categories of responses to aortic
banding. We compared gene expression levels in NF, F, and FS, at a 1.2 cutoff. Because the
category FS=F did not include SERCA2a targets, it was excluded. We ended up with 3x3x2= 18
(NF, F, FS) configurations, only 12 of which were possible in real space. SERCA2a effect was
significant in 10 of these solutions (Fig 5).
In profile 1 (Fig 5, A, B), the gene expression level is stable from NF to F. This gene is not in the
natural repertoire of compensatory reactions against aortic banding. Here SERCA2a is bringing a
new adaptive reaction to overload. In profiles 5 and 7, the natural responses to aortic banding are
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maladaptive. In profile 5, the gene expression level will be restored back to its level is normal
hearts. The response is maladaptive and is cancelled. In profile 7, the adaptive response
(SERCA2a) is the opposite of the natural response to aortic banding. For profiles 3 and 9 the
response in F maybe adaptive, a first step in the right direction that needs optimization, or it
maybe maladaptive. For profile 3, since the more adaptive gene expression level is in between
and different from gene expression levels for NF and F, survival is most probably a non-linear
function of transcriptional activity, and we cannot tell if the level in F is adaptive as compared to
NF and being optimized, or maladaptive. For profile 9, if survival increases linearly in the range
NF to FS with increasing level of gene product, than the response in F is adaptive as compared to
NF but not as adaptive as in FS. The natural response to aortic banding was amplified by
SERCA2a. On the other hand, if survival is a non-linear function of transcriptional activity, then
the response in F maybe maladaptive as compared to NF.
The same applies to the mirror images of these individual profiles.
Using the same primary data set, the program Cluster (M. Eisen;
http://rana.lbl.gov/EisenSoftware.htm) (10) failed to reproduce the clustering obtained with our
algorithm unless the already clustered output from our algorithm was submitted. This further
demonstrates the need to incorporate specific biological knowledge and guidance into the
mathematical framework for gene expression analysis.
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What genes encode natural adaptive responses to aortic banding, needed for clinical non-
failure?
There are two categories of responses to aortic banding that are needed to have clinical non-
failure. We examined SERCA2a-induced responses earlier. The other category are natural
adaptive responses needed for non-failure. Those are the genes that have a stable expression in
failure and SERCA2a-induced non-failure, yet are responses to aortic banding, they are
reprogrammed in failure. A natural adaptive response that is optimized and needed for non-
failure, will be conserved from failure to SERCA2a-induced non-failure. Those genes are not
targets of SERCA2a (or other components of the SERCA2a construct). Their level of expression
is the same across all aortic-banded states F, FV and FS, since they are a reaction against this
insult. Out of 2006 genes changed from NF to F (those are the natural responses against aortic
banding), 226 genes were found to encode optimized adaptive responses against aortic banding
that were conserved when SERCA2a infected the cells (Fig 6).
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Distribution of genes by biological functional category reveals patterns in the genetic
reprogramming events to reverse heart failure:
We further classified genes from Figure 5 and 6 according to their published biological function
available in public databases (NCBI).
SERCA-induced responses vs. Natural adaptive responses (i.e. Figure 5 vs. Figure 6 genes):
As expected (Figure 7), SERCA2a targets are more often Ca2+ signaling genes than the natural
adaptive responses to aortic banding from Figure 6. Up to 15% of SERCA2a targets function in
Ca2+ signaling pathways, while 2% function in Ca2+/Calmodulin signaling. This may offer a
mechanistic model for SERCA2a targeting of these genes, namely that SERCA2a effect on these
genes is mediated by Ca2+. The Figure also shows that natural adaptive responses are much
more biased towards mitochondrion and metabolism/energy responses, whereas SERCA2a
targets more specifically the cytoskeletal pathways and extracellular matrix components, for
structural and contractile optimization on the one hand, and remodeling on the other.
As expected, the genes upregulated in failure in Figure 5 vs. in Figure 6 (see Figure 8A) fall in
different categories since the changes in Figure 6 are going to persist into the FS state (adaptive
responses) whereas most of the responses in Figure 5 are maladaptive and are going to be
corrected by SERCA2a (downregulated). The same applies to Figure 8B. In Figure 8A, a large
proportion of genes activated in both Fig 5 and 6 belong to the development/growth
differentiation categories; organs use as defense mechanism genetic programs already used
during evolution and embryological development of the organ.
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SERCA2a and adaptive natural responses target different functional categories of genes:
Comparison of genes activated by SERCA2a vs. genes naturally activated in response to aortic
banding (Figure 9A), shows that SERCA2a specifically activates genes in the cytoskeleton,
ECM, and Ca2+ signaling categories, while activation by SERCA2a of the cell cycle, growth
and development genes is comparable to that achieved naturally.
In Figure 9B, the pattern of gene inactivation by SERCA2a and natural responses is more
comparable, except for a larger proportion of mitochondrial and metabolism energy genes being
turned off by natural adaptive responses.
SERCA-induced responses (Figure 5 genes):
SERCA2a activates and inactivates different categories of genes:
SERCA2a activates genes in the cytoskeleton, ECM, Ca2+ signaling, signal transduction, cell
cycle, growth and differentiation pathways, and inactivates genes mainly in the signal
transduction, transcription, cell cycle and metabolism/energy categories (Figure 10).
Comparison of genes in profile 1 and profile 2 of Figure 5 (Figure 11 A), demonstrates an
important activation of cytoskeletal, Ca2+ signaling, signal transduction, cell cycle and
development and growth genes. In contrast, metabolism genes are inactivated, in addition to
other genes involved in the cell cycle.
Comparison of profiles 5 and 6 (Figure 11 C) reveals that signal transduction, cytoskeletal, Ca2+
signaling, RNA processing/translation, cell cycle and development growth and differentiation
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genes are activated with SERCA2a restoration, while prominently transcription, and
metabolism/energy genes are inactivated.
Among the genes that were upregulated in failure and then restored to non-failing levels by
SERCA2a (Fig 5, profile 5) is notably tau protein kinase 1 (GSK3beta) which is known to
protect from cardiac hypertrophy as well from apoptosis in the heart (17, 18). GSK3beta was
upregulated 1.3 folds upon cardiac failure. It is a kinase with profound effects on fetal
development and tumorogenesis. A Ca2+-mediated or direct interaction between SERCA2a and
the PI3K/GSK3beta pathways (17, 18) has recently been described. The activity of GSK3beta is
negatively regulated by Akt in many cell types, and inhibiting GSK3beta seems to be critical to
the anti-apoptotic effect of Akt and to the hypertrophic response (17).
Interestingly, Akt was found to be decreased in failing hearts and rescued by overexpression of
SERCA2a (Figure 5, profile 6). Akt is a powerful survival signal in many systems and is
activated by several cardioprotective ligand-receptor systems including insulin-, IGF- I- and
gp13O-signaling pathways. Its rescue probably plays a very important role in the survival benefit
observed with SERCA2a overexpression.
Furthermore, two upregulated genes in failure (Figure 6, profile 2) interact with Akt. Akt
phosphorylates PEA 15 (19) to stabilize its anti-apoptotic function. Hsp 27 was found to regulate
apoptosis by regulating Akt activation (20).
Among the failing downregulated genes that were rescued by SERCA2a (Fig 5, profile 6) was
the small peptide Tensin. This protein localizes to focal adhesions, regions of the plasma
membrane where the cell attaches to the extracellular matrix. This protein crosslinks actin
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filaments and contains a Src homology 2 (SH2) domain, which is often found in molecules
involved in signal transduction. Tensin is a substrate of calpain II. Tensin is part of the integrin
complex consisting of structural and signaling proteins serving both as physical link between the
extracellular matrix and the cytoskeleton as well as signal transduction (21-24). The
normalization of Tensin gene expression by SERCA2a gene transfer in the failing heart may
represent an interesting target in cardioprotection from apoptosis and cell survival signaling
pathways in heart failure.
Interestingly, Tropomyosin 1 is downregulated in failure and rescued with SERCA2a infection
(Fig 5, profile 6). Mutations in this gene cause hypertrophic cardiomyopathy (25). Tropomyosin
1 is a structural component of the cytoskeleton that binds actin and has an important role in
regulation of muscle contraction and heart rate.
Activins are dimeric differentiation and growth factors belonging to the transforming growth
factor-beta (TGF-beta) superfamily of signaling proteins. Activins signal through a heteromeric
complex of receptor serine kinases. The receptors are transmembrane proteins, composed of a
ligand-binding extracellular domain and a cytoplasmic domain with serine/threonine specificity.
Type I and II receptors form a stable complex after ligand binding, where type II receptor
phosphorylates type I receptors (26). The gene that encodes Activin A type I receptor which
signals a particular transcriptional response in concert with activin type II receptors, was found
to be restored by SERCA2a from a downregulated state in failure (Figure 5, profile 6). The
follistatin-like gene, which was increased in failure (Figure 6, profile 2) is an Activin binding
protein which also binds Ca2+ (27).
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Heme oxygenase (Fig 5, profile 8) is downregulated in failure (6 fold) and then strongly
upregulated upon SERCA2a infection (9 fold). It is an essential enzyme in heme catabolism that
cleaves heme to biliverdin. It is also involved in signal transduction and activates the NF-kappaB
and MAPK signaling pathways (28). It is an interesting candidate in failure reversal because of
its prominent roles in cardiovascular pathways: It is a survival signal (29); it protects against
oxidative stress; it binds nitric oxide (30); and it regulates the cell cycle in vascular endothelial
and smooth muscle cells (31).
In profile 9 of Figure 5 (Figure IIE), activation of genes for ECM molecules, Ca2+ signaling,
signal transduction, cell cycle, growth and development appears to be amplified.
Among the amplified responses by SERCA2a (Figure 5, profile 9) are Endothelin receptor type
B (Ednrb), and the mitochondrial uncoupling protein 2 (UCP2). Endothelin receptor type B is a
G protein-coupled receptor which activates a phosphatidylinositol-Ca2+ second messenger
system. Its ligand, endothelin, is a potent vasoactive peptide. Endothelin plays an important role
in the pathophysiology of idiopathic dilated cardiomyopathy (32). It is involved in hypertension
(33), in development (34), and it activates matrix metalloproteinases (35) important for
remodeling.
Mitochondrial uncoupling proteins separate oxidative phosphorylation from ATP production by
allowing a leak in the transmembrane proton gradient. UCP2 overexpression prevents
mitochondrial death pathways in cardiomyocytes, by protecting them from oxidative stress
induced apoptosis. UCP2 overexpression dramatically attenuated both Ca2+ overload and the
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production of reactive oxygen species in mitochondria, which contribute to the catastrophic loss
of mitochondrial inner membrane potential, a critical early event in cell death (36, 37).
Natural adaptive responses (Figure 6 genes):
Comparison of genes in profiles 1 and 2 of Figure 6 (Figure 12) shows that the metabolic/energy
and mitochondrial pathways are inactivated, at the expense of a dramatic activation of cell cycle,
development and differentiation, cytoskeletal and ECM genes.
Among the genes downregulated in failure is S100 calcium binding protein Al (Fig 6, profile 1).
This protein is a member of the S100 family of proteins containing 2 EF-hand calcium-binding
motifs, involved in the regulation of cell cycle progression and differentiation. This protein
stimulates Ca2+-induced Ca2+ release, inhibits microtubule assembly, and inhibits protein
kinase C-mediated phosphorylation. Reduced expression of this protein has been implicated in
cardiomyopathies. It is specifically expressed in the heart at high levels and is thought to be an
important regulator of cardiac contractility (38). SIOOAI protein acts as a cardioprotective factor
during ischemic myocardial injury by inhibiting apoptosis in cardiomyocytes via activation of
the extracellular signal-regulated protein kinase 1/2 (ERKl/2) (39). This protein also enhances
sarcoplasmic Ca2+ release in skeletal muscle fibers (40). Therefore its downregulation in failure
would counteract Ca2+ overload in the failing myocardium.
K+ channels:
The K+ channel was repeatedly targeted. Most of the ion channels genes that were
reprogrammed were K+ channels. K+ channels were also affected by the reprogramming of
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other genes. This important function for K+ channels in failure reversal is understandable in the
light of the strong mechanistic role for K+ currents as underpinning excitation-contraction
coupling in the heart along with Ca2+.
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Validation of microarray data:
Quantitative Reverse Transcriptase PCR (QRT-PCR) validates microarray data:
QRT-PCR was performed to validate that the microarray data reflects true transcriptional
changes. In Figure 14 the profiles of different up-regulated and down-regulated sample genes
obtained from the microarray data analysis were compared to the QRT-PCR profiles for the
corresponding genes, showing a close correspondence of the data for the two analytical
methodologies. The fold changes determined from microarray data analysis and QRT-PCR
analysis were used to plot expression profiles, setting the level of the NF sample to 100. As
shown, QRT-PCR results track the changes in transcript profiles for Tensin, GSK-3, Rev-ErbA-
a, P-enolase, Atrial Myosin Light Chain 1, Na-channel, Rev-ErbA-3, and Connexin-43 gene.
Other published studies validate microarray data:
Other studies in the literature recorded gene expression changes in failure (Figure 6) similar to
our microarray data for genes: SLC2A4 (a glucose transporter), the mitochondrial uncoupling
proton carrier UCP3 (41), ICAM1 (42), BNP (43), Natriuretic Peptide Precursor A (41), and
Endothelin converting enzyme 1 (44).
Microarray data has its internal controls:
We repeatedly found that genes represented by more than one array element or with high degrees
of sequence identity clustered next to each other.
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IV Discussion
In the post-genome era, biology is quickly transforming from a data poor to a data rich science,
but it still lacks the tools to extract meaningful information from the flood of data. The interface
between disciplines is oftentimes a rich reservoir of ideas, and biology needs to take advantage
of the rapid expansion of interdisciplinary research, to borrow approaches from other disciplines
to extract functional information from its growing share of data. One field which would benefit
from such an exchange of ideas is gene expression analysis. Most current attempts to analyze
large genomic and proteomic data sets look for specific patterns in the data, focusing on the data
generated by a system and treating the system as a black box. This approach does not say much
about the underlying mechanisms, a knowledge of which is needed for real-life problem solving,
and also limits the analysis to relatively simple systems. This explains why most current gene
expression analysis are limited to comparing two groups only. By combining model- and data-
driven approaches, we were able to analyze a complex multivariate genome-wide microarray
expression dataset. It allowed the isolation of novel genes involved in the pathophysiology of
heart failure and its reversal that will be used to guide future therapeutic interventions.
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Its reliance on the combinatorial control of gene expression in mammals, a widespread control
mechanism for gene expression, to dissect causal contributions in multivariate transcriptional
networks, is one aspect of the portability of this gene expression analysis.
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Cardiovascular compensatory responses in heart failure are adaptive on the short-term but
maladaptive on the long-term:
Evidence from drug trials in heart failure showed that drugs that improve short-term symptoms,
worsen long-term survival. Furthermore, the ability of neurohumoral blockade (-blockers) and
ACE inhibitors to prolong survival and improve symptoms, have shown that although these two
responses are initially adaptive and improve hemodynamics, they evoke long-term proliferative
responses that are deleterious. The long-term beneficial effect of many drugs used in heart failure
is due to their slowing of the progressive ventricular dilatation called remodeling.
Neurohumoral/hemodynamic activation, and hypertrophy/architectural changes (remodeling) in
failing hearts are adaptive on the short-run but maladaptive on the long-run. Hypertrophy is
initially adaptive, but on the long-term causes maladaptive responses that dominate the clinical
picture and hasten the deterioration of the failing heart (45).
The heart lacks functional redundancy. The heart is unlike any other organ in terms of the
selective pressures that shaped its evolution. Our view of the heart as central for mammalian
survival is because it is afunctional unit with no functional redundancy (the right ventricle is a
low pressure chamber, the left ventricle has no functional redundancy). The heart is one of the
very few biological systems important for survival that have no functional redundancy. For this
reason, the heart will prioritize uninterrupted function. Its response to an insult is unique among
organs: because there is no functional redundancy at the level of the pump, and the life of the
whole organism depends on an uninterrupted blood supply, the heart cannot afford resting to heal
while another part takes over function, like what happens in most other organs. This puts a major
37
constraint on the types of compensations that can take place. Any compensation in this context
must prevent cardiovascular collapse at all price.
Compensatory responses have short-term and long-term consequences. In the case of an insult,
organs that have functional redundancy will tend to select adaptive long-term responses even if
the responses are functionally maladaptive on the short term: the rest of the organ will take over
function in the meanwhile. This increases reproductive span. The heart, however, does not have
this luxury and will therefore prioritize short-term over long-term adaptiveness. In the case of a
non-redundant system, long-term adaptiveness does not exist in the absence of short-term
adaptiveness: the organism will not survive a maladaptive short-term response. A response that
carries a necessary immediate survival advantage, even if maladaptive on the long-term, will be
selected.
In heart failure, most responses that are adaptive on the short-term exclude long-term adaptivity.
Proliferative responses in the heart lead to cell death. The failing heart deteriorates rapidly.
Insults that increase the load on organs induce proliferative responses leading to hypertrophy and
hyperplasia. In the case of the heart, because of the lack of redundancy and the need for
continued function and ordered electrical impulse propagation, cells cannot divide in any
significant amount. Forcing adult myocytes into the cell cycle leads to apoptosis (46). There is
also evidence that hypertrophy itself leads to cell death by mechanisms independent of cell-cycle
induction. So proliferative signals lead to hypertrophy and cell death. From here emerges the
picture of the vicious downward spiral of heart failure: increased load -+ proliferative signaling
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-+ hypertrophy -- cell death -+ increased load. Thus it appears that in the case of heart failure,
the consequences of short-term responses would preclude long-term survival.
The Neurohumoral/hemodynamic defense reactions emerged as a response to acute challenges.
The neurohumoral/hemodynamic defense reactions act on the heart, blood vessels and kidneys,
to compensate for the fall in blood pressure caused by underfilling in the systemic arterial system
during exercise and blood loss. Because of their high survival value in acute fight or flight
situations and in hemorrhage, these hemodynamic responses emerged as an adaptation for these
short-term challenges, however they can become maladaptive when used in long-term
challenges, such as chronic illness, like heart failure, where it is the cause of a downward
deleterious spiral (47). Natural selection favored much more heavily responses that are adaptive
for these short term challenges, because they carry a high survival value, are very common, and
occur throughout life, i.e. especially before the reproductive age, as opposed to heart failure.
Heart failure usually occurs after peak reproductive age. This is another important reason why
compensatory responses in heart failure are not optimized. The major etiologies of heart failure
in developed countries are coronary and hypertensive heart disease. Any disease whose onset is
after peak reproductive age will for the most part escape natural selection. A dominant defective
gene that manifests through a disease phenotype before reproductive age will be filtered through
natural selection in one of two ways: Either the gene will be eliminated from the gene pool
because of a decrease in reproductive fitness, or adaptive responses by other genes, either a
change in a the transcriptional state or a mutation in another gene (or group of genes) will
compensate for the decrease in reproductive fitness and lead to an increase in the gene pool (co-
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segregation) of the defective and compensatory mechanisms. In such individuals, the disease
might be sub-clinical and undetected, or have a later onset. Because heart failure occurs mostly
after reproductive age, most of the compensatory responses that develop are not filtered for
adaptive responses by natural selection, therefore a lot of them would be predicted on these
grounds alone to be maladaptive, and this is in agreement with observations.
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SERCA2a targets a key signaling pathway in the heart cell:
Heart muscle cells make extensive use of Ca2+ signaling, where it assumes a central role in
excitation-contraction coupling. Ca+ can be used as a signal because its cytosolic concentration
is normally kept very low (~I0- 7M), whereas its concentration in the extracellular fluid (~10- 3M)
and ER lumen is high. Heart failure leads to increased cytosolic Ca2+ (48) (49). Impaired
SERCA2a activity is thought to be one of the main mechanisms for abnormal Ca2+ handling in
heart failure (7). Ca2+ has been implicated as a possible cause of necrosis and apoptosis in the
overloaded myocyte (48, 49). One way to understand the pathogenic role of Ca2+ overload in the
failing heart is in thermodynamic terms. In the failing heart, Ca2+ increases energy demands and
decreases energy production and leads to a vicious cycle of energy starvation. On the other hand,
because Ca2+ level in the cell is normally very tightly regulated, when it increases in the cytosol
it tends towards the extracellular/ER Ca2+ concentration, and this can be viewed as an entropic
drive that signals cell death.
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Unknown genes impact the interpretation of function distribution graphs (Figures 7-13):
In the interpretation of the graphs showing the distribution of genes according to function, one
has to take into account the fact that a large percentage of the genes belong to the unclassified
category. More than 90% of genes in the unclassified category are unknown, i.e. they are
transcripts that do not match a gene of known function. The rest (<10%) are genes of known
function that do not belong to one of the listed categories. Because the number of classified
known genes in the distribution is large enough, one can predict based on population statistics
that the unknown gene population most probably obeys the same functional distribution as the
known classified gene population, and therefore one should account for the proportion of
unclassified genes in the interpretation. The easiest interpretation is when both compared
categories have a very low and similar percentage of unclassified genes, or when the percentages
of unclassified genes are similar.
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Choice of a cutoff value:
A small transcription signal, like a transcription factor, located high up in a transcriptional
amplification pyramid, can produce a large transcriptional change at lower levels in the pyramid.
Therefore, the level of a transcription factor that initiates a transcriptional programme is expected
to be tightly regulated, and even a small change from its basal level will produce a downstream
response. Such important signals will often be missed in expression profiles that rely on large
fold changes. One has to balance the need to unravel true effects against losing important
information. Current array technology is mostly used as a jump stone for further confirmation by
other experimental methods, and therefore one has more tolerance for false positives than false
negatives. It is not more stringent to use a higher fold change as a cutoff when you are using it as
a measure of change and no change. You get a compromise: It is stringent when you are using it
as a measure of change, but it is not stringent when you are using it as a measure of no change.
Thus, a compromise is made when a cutoff is used as both a measure of change and no change.
For example, when 1.2 is used as a measure of no change, it is stringent.
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Limitations:
As a first limitation, the use of RNA extracted from the entire heart may confound the
interpretation of some results due to the heterogeneity of cell types. In addition, with even the
best-controlled experimental setting, expression of the transgene is exhibited in 30-60% of
cardiac cells following gene transfer. This variability may affect gene expression.
A considerable variability in studying gene profiling in pathological diseases, including heart
failure, has been described, compared to the variability related to the experimental error once
stringent parameters are included. Multiple samples and sample repetition reduce but do not
eliminate biological variability. Although less relevant specifically for human disease, this study
has been initially conducted in a rat model of heart failure and gene transfer where the biological
variability within samples is largely reduced by homology of gender (all male rats), age, absence
of other disease conditions, medications and disease etiology uniformity. In our study the
biological variability is more restricted to the genetic intervention such as the level of viral
transfection.
Many genes have alternative splice sites and this may lead to apparently contradictory results for
array elements interrogating different regions of one transcript. Such genes are usually excluded
from the analysis although they may be functionally important.
The list of genes does not provide a mechanism for all the perturbed genes. Genetic editing by
transgenesis or knock-out would be required for each gene to clearly understand gene specific
mechanisms.
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V Conclusion
First, we have described a novel, powerful and portable method to elucidate multivariate
genome-wide transcriptional networks from primary microarray data. As opposed to current
attempts to analyze large genomic and proteomic data sets that focus only on the data generated
by a system, we have combined model and data-driven approaches, what enabled us to elucidate
multivariate transcriptional profiles and classify them into multiple functional classes.
Second, as a result, new genes have been identified that may prove important in understanding
the mechanisms of heart failure and its reversal. The observation that most compensatory
responses in heart failure are maladaptive suggests that successful new therapeutics might be
aimed at the upstream signal-transducing molecules whose activity in the failing hearts leads to
expression of pathological transcriptional programs. This study serves as a step toward defining
new therapeutic molecular targets in heart failure and demonstrates the potential power of well
designed gene expression analyses to identify therapeutic targets in disease states.
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Figure 1:
SERCA2a does not act on a blank slate. Starting all the way back from a non-failing heart, we
wanted to define the genetic reprogramming required to have non-failure in the face of aortic
banding (a reprogrammed gene is a gene whose expression is changed). The reversal of heart
failure by SERCA2a is a two-step process in a sequence. In a cause-effect sequence, change
explains change (A). The change in inputs explain the change in outputs of the system. Here, the
change in inputs explains the change in gene expression. In the NF to F sequence, the input
introduced is aortic banding (it is also sustained in time). The genes changed between states NF
and F are therefore natural responses to aortic banding; some are adaptive, other maladaptive.
Some of the genes changed from NF to F are natural adaptive responses to aortic banding needed
for clinical non-failure. In the F to FS sequence, the input introduced is SERCA2a gene transfer
(in its adenoviral construct). Therefore some of the genes changed between states F and FS are
SERCA2a-induced responses to aortic banding. SERCA2a does not act on a blank state, it acts
on a basis of natural adaptive and maladaptive responses to aortic banding. If we start at point F
in time, the only genetic reprogramming needed to have clinical non-failure are SERCA2a-
induced responses to aortic banding. If however we go back to point NF in time, in order to have
clinical non-failure, we need both the natural adaptive responses to aortic banding needed for
non-failure, and the SERCA2a-induced responses to aortic banding. We identified these two
functional categories of genes.
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Figure 2:
The heart cell is the signal processor in an input-output model of gene expression. This
model forms the basis of gene expression analysis in this study. The cardiac myocyte is the
signal processor that integrates the aortic banding input at time 1, and the gene transfer input at
time 2. Notice how the two levels of input are reproduced in the two levels of output: A heart cell
can change the expression of its genes and acquire a new molecular phenotype in response to
external functional/structural signals (aortic banding) and to internal molecular signals (gene
transfer). The new molecular phenotype at the level of the cell will translate into an altered
structure and function at the level of the heart and cardiovascular system, and this new clinical
phenotype can be assessed by echocardiography and other clinical parameters. The aortic
banding input is transduced at the level of the cell into a molecular signal which is relayed to the
nucleus where it alters gene expression. The clinical phenotype difference between the different
samples is caused by an underlying molecular phenotype difference.
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Figure 3:
Gene expression is regulated by combinatorial control. The transcriptional activity of a gene
results from a competition between activators and repressors. Combinatorial control of gene
expression can be modeled by a vectorial representation of an input-output system. Multiple
inputs interact to control the expression of a gene in each experimental sample. The different
inputs will lead to different combinations of signals that will affect the expression of a gene. The
promoter of a gene will integrate activator and repressor signals from this combination of inputs,
and then make a decision to turn a gene ON or OFF. Transcriptional activity is measured by
mRNA abundance of a gene for that experimental sample. Shown in color are the inputs that
account for differences in expression level of a gene between two experimental samples. The
positive direction for vectors is the direction of increased gene expression.
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Figure 4:
The thirteen possible configurations for the relative expression level of a gene across the
three experimental samples F, FV and FS. In order to know which genes were targets of
SERCA2a, we analyzed the different configurations, and assigned to each the probability of
being described by a gene which is a SERCA2a target. We found that a gene probably affected
by SERCA2a is a gene where the expression level in FS is different from FV, and FS is different
from F. Of those genes, a gene that fits configurations 11 and 13 has the highest probability of
being a SERCA2a target; configurations 1, 10, 5, and 6 are high probability; configurations 3 and
8 are lower probability.
Solving for SERCA2a target genes: For each configuration, we wrote down all the possible
solutions to the system of 3 equations with 4 unknowns. Then out of all possible solutions, we
chose the most parsimonious solution. We illustrate this by solving configuration 1:
System of 3 equations with 4 unknowns:
[2]-[1]: V + GFP+ BGal = FV - F
[3] - [2]: SERCA - BGal = FS - FV
[3]-[1]: V + GFP +SERCA = FS - F
For configuration 1, it corresponds to:
[2] - [1]: V + GFP + BGal > 0
[3] - [2]: SERCA - BGal >0
[3]-[1]: V+GFP+ SERCA>0
All possible solutions to the system:
Solution 1:
V>0
SERCA>0
Solution 2:
GFP>0
SERCA>0
Solution 3:
BGal>0
SERCA>O
SERCA>BGal
Solution 4:
BGal<0
V>0
V>IBGall
55
Solution 5:
BGal<O
GFP>O
GFP>IBGall
Solution 6:
V>o
GFP>O
SERCA>O
Solution 7:
Solution n:
V>o
GFP>O
SERCA>O
BGal>0
SERCA>BGal
Out of all the possible solutions, the most parsimonious are solutions 1 and 2 (in solution 3 the
magnitudes of the vectors are important, which is not the case in solutions 1 and 2):
Parsimony Solution 1 (PS1): SERCA2a>O and V>O
PS2: SERCA2a>O and GFP>O
Analysis of each individual configuration:
Configuration 1:
PSI: SERCA2a>O and V>O
PS2: SERCA2a>O and GFP>O
Mixed virus/SERCA effect.
Virus effect present, SERCA effect is present.
Molecular-Clinical Correlation (MCC): double correlation (F to FS and FV to FS).
High probability of being a SERCA2a target.
Will be considered as a potential SERCA2a target.
Configuration 2:
PSI: V>O
PS2: GFP>O
Pure virus effect.
No SERCA effect.
MCC: single correlation.
Probability of being a SERCA2a target ~ 0.
Will not be considered.
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Configuration 3:
PSI: V>O and B-Gal>O
PS2: GFP>O and B-Gal>O
PS3: SERCA2a>O, B-Gal>O, SERCA2a<B-Gal
PS4: SERCA2a<O, V>O, V>SERCA2a
PS5: SERCA<O, GFP>O, GFP>SERCA2a
Pure Virus effect, or Pure SERCA2a effect, or Mixed virus/SERCA effect.
MCC: double correlation.
Lower probability of being a SERCA2a target.
Will be considered.
(Special case: The solution that includes SERCA2a respects the least number of causes
condition, but has one more constraint. It is tolerated however, at the price of a lower probability
score, because of a double molecular/clinical correlation, and we assume that the clinical
difference is caused by SERCA2a).
Configuration 4:
PS: B-Gal>O
No SERCA2a effect.
MCC: single correlation.
Probability of being a SERCA2a target ~ 0.
Will not be considered.
Configuration 5:
PS: B-Gal>O, SERCA2a<0
Probably a pure SERCA2a effect
MCC: double correlation.
High Probability of being a SERCA2a target.
Will be considered.
Configuration 11:
PS: SERCA2a>0
No virus effect.
Pure serca effect.
MCC: Corresponds to clinical phenotype in the 3 conditions perfectly.
Highest probability of being a SERCA2a target.
Will be considered.
Configuration 12:
PS: V = GFP = B-Gal= SERCA2a = 0
No serca effect.
No virus effect.
MCC: single correlation.
Probability of being a SERCA2a target ~ 0.
Will not be considered.
And the mirror images of these individual cases.
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By virus effect we mean any difference in expression level between FS and F, due to SERCA2a
construct components distinct from SERCA2a: adenoviral genes, or GFP.
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Figure 5:
Transcriptional profiling of SERCA2a targets defines ten categories of responses against
aortic banding. Depicted in (A) is a hierarchical clustering analysis of gene expression data
from the 473 gene targets of SERCA2a. Each row represents a separate transcript on the
microarray and each column a separate mRNA sample. Each small red bar indicates that the
given gene in the given sample is expressed at a level higher than the mean across all samples.
Each small green bar indicates a less-than-average expression level, and each black bar denotes
an expression level that is close to the mean. The color intensity represents the magnitude of the
deviation from the mean (10), and is depicted according to the color scale shown at the bottom.
(B) shows the 10 possible transcriptional profiles for SERCA2a target genes. The 473 genes
were first clustered by our algorithm according to the profiles in (B) before they were submitted
to a hierarchical clustering algorithm for visualization (A). (C), Hierarchical clustering was
applied to a 118 gene subgroup of the 473 genes in (A), selected because they had the highest
probability of being targets of SERCA2a. In another visual representation of the results for this
subclass of genes (D), the use of a common reference microarray (NF) allows the comparison of
the relative expression level of each gene across all the experimental samples. Notice the plateau
between the samples F and FV indicative of a pure SERCA2a effect accounting for the gene
expression level in FS.
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Figure 6:
There are natural adaptive responses to aortic banding that are needed for clinical non-
failure. Depicted in (A) is a hierarchical clustering analysis of gene expression data from the 226
genes that encode natural adaptive responses to aortic banding needed for clinical non-failure.
(B) shows the 2 possible transcriptional profiles for such genes. The 226 genes were first
clustered by our algorithm according to the profiles in (B) before they were submitted to a
hierarchical clustering algorithm for visualization (A). Notice how the transcriptional states
change from absence to presence of the aortic banding insult (NF to F), and how they are
sustained in the presence of aortic banding (F, FV, FS), pointing to their crucial/important
compensatory role. These genes are not affected by SERCA2a, yet they are essential for non-
failure.
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Figures 7-13:
Distribution of genes by functional category. The genes are classified according to biological
function from information available in public databases (NCBI EntrezGene; and NCBI UniGene,
an EST database). Multiple comparisons are performed to expose important functional patterns
underlying the genetic reprogramming that takes place to reverse heart failure. Some genes
belong to more than one functional category, therefore percentages may not add up to 100%. All
genes under category Ca2+/Calmodulin signaling are part of the higher category Ca2+
binding/Ca2+ signaling. In addition, all genes under metabolism/energy: lipids,
metabolism/energy: carbohydrates, and metabolism/energy: proteins, belong to the same higher
category metabolism/energy. More than 90% in the "unclassified" category are unknown, i.e.
they are transcripts that do not match a gene of known function. Less than 10% of the
"unclassified" transcripts have a known function but do not belong to any of the listed categories.
ECM= Extracellular matrix.
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Figure 14:
Quantitative Reverse transcriptase PCR (QRT-PCR) validates microarray data.
Gene expression levels obtained from QRT-PCR experiments track the changes recorded in the
microarray experiments, thus validating the microarray results.
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Figure 14 A:
beta-Enolase: QRT-PCR validates microarray data
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Figure 14 B:
Na channel: QRT-PCR validates microarray data
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Figure 14 C:
Atrial Myosin Light Chain 1: QRT-PCR validates microarray data
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Figure 14 D:
Connexin 43: QRT-PCR validates microarray data
-+- Microarray
-U- QRT-PCR
NFV NFS F
160 -
140 -
U
z
0
120
100
80
60 -
40 -
20 -
0
FV FSNF
Figure 14 E:
Tensin: QRT-PCR validates microarray data
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Figure 14 F:
Rev-ErbA-beta: QRT-PCR validates microarray data
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Figure 14 G:
GSK 3-beta: QRT-PCR validates microarray data
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Figure 14 H:
Rev-ErbA-alpha: QRT-PCR validates microarray data
-+- Microarray
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Table 1:
This is a list of all the 473 candidate gene targets of SERCA2a. The candidate gene probability
of being a SERCA2a target is noted in the last column. Those genes correspond to the genes
depicted in Figure 5A. The genes in the highest probability category were depicted in Figure 5D.
The different fold changes that were used in the analysis are also found in the table. Genes where
the fold change FS/FV > 2 or < 0.5, AND where FS/F > 2 or < 0.5, were shaded in gray, and may
be important targets of SERCA2a in addition to the genes in the Highest probability category.
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Table 1.1
Genes corresponding to Figure 5, Profile 1
Probe Set Accession # Gene Function FV/F FSTV FST F/NF FV/NF FS/NF Probability
AF085693_at
rcAA800737_at
rcH31847_at
rcAA817892_at
AF034582_at
M83196_at
D16237_at
X16002cds s at
X52619_at
X06801cds f at
S77858_s_at
rcAA866293_at
M17526_at
rcAA875523_i at
M58758_at
D16309_at
M55015cds_s_at
S69383_at
AF085693 Git: G protein-coupled receptor
kinase-interactor 1
AA800737 similar to PKP4: plakophilin 4
H31847 Dnclil: dynein, cytoplasmic, light
intermediate chain 1
AA817892 Gnb2: guanine nucleotide binding
protein, beta polypeptide 2
AF034582 VAP1: vesicle associated protein
M83196 Mtapla: microtubule-associated
protein 1 A
D16237 Cdc25b: cell division cycle 25B
X16002
X52619
X06801
S77858
AA866293
M17526
Kcna4: potassium voltage gated
channel, shaker related subfamily,
member 4
Rp128: ribosomal protein L28
Vascular alpha-actin
Non-muscle myosin alkali light chain
unknown
Gnao: guanine nucleotide binding
protein, alpha o
AA875523 similar to MYL6: myosin, light
polypeptide 6, alkali, smooth muscle
and non-muscle
M58758 Atp6n1a: ATPase, H+ transporting,
lysosomal noncatalytic accessory
protein 1a
D16309 Ccnd3: Cyclin D3
M55015 Ncd: Nucleolin
S69383 Alox12: arachidonate 12-lipoxygenase
M57664_g_at M57664 Ckb: creatine kinase, brain
signal transduction/G protein
coupled/GTPase activation
cell adhesion/cytoskeleton
GTPase signal transduction/motor
activity/cytoskeleton
G Protein/signal transduction/GTPase
intracellular trafficking
cytoskeletal/development
cell cycle/tyrosine phosphatase
K channel voltage gated/regulation of
EC coupling
ribosome
cytoskeleton
myosin/Ca-binding/cytoskeleton/motor
unknown
G protein/GTPase/Ca-
signaling/cytoskeletal rearrangement
myosin/Ca-binding/muscle
contraction/cytoskeleton/motor
proton transport/receptor medicated
endocytosis
cell cycle
ribosome synthesis/cell cycle
signal transduction/cell cycle
energy homeostasis/creatine kinase
0.90 1.33 1.20 1.08 0.98 1.30 highest
0.90 1.36
0.86 1.42
1.22 1.11 0.99 1.35 highest
1.22 1.02 0.88 1.25 highest
1.02 1.20 1.23 1.16 1.19 1.43 highest
0.98 1.27 1.25 1.02 1.01 1.27 highest
0.90 1.40 1.27 1.18 1.07 1.50 highest
0.99 1.28 1.27 1.19 1.18 1.51 highest
1.05 1.24 1.31 0.94 0.99 1.23 highest
1.07 1.22 1.31 0.97 1.04 1.27 highest
1.09 1.22 1.32 1.07 1.17 1.42 highest
1.05 1.26 1.33 1.20 1.26 1.60 highest
0.97 1.38 1.33 0.93 0.90 1.24 highest
1.08 1.24 1.34 1.01 1.09 1.35 highest
1.11 1.23 1.36 1.13 1.26 1.54 highest
1.01 1.36 1.38 0.89 0.91 1.23 highest
1.19 1.20 1.42 0.94 1.12 1.34 highest
1.17 1.23 1.44 0.87 1.02 1.25 highest
0.96 1.56 1.51 1.10 1.06 1.65 highest
1.03 1.50 1.54 0.90 0.93 1.39 highest
I
M17526_g_at
X78949_at
U08136at
U36482_at
AJ006971_at
rcAA893235_at
M89646_at
AJ010351_s_at
L25527_at
L02529_at
S54008_i at
M80804_s_at
rcAA891242_at
rcAA891242gg_at
M24852_at
M17526 Gnao: guanine nucleotide binding
protein, alpha o
X78949 P4HA1: procollagen-proline, 2-
oxoglutarate 4-dioxygenase (proline 4-
hvdroxvlase). alDha oolvoeotide I
U08136
U36482
AJ006971
AA893235
M89646
AJ010351
L25527
L02529
S54008
M80804
AA891242
AA891242
M24852
G protein/Ca-signaling
collagen synthesis/ECM
myosin/Ca-binding/muscle
contraction/muscle
development/cytoskeleton
myosin/Ca-binding/muscle
contraction/muscle
development/cytoskeleton
Ca-binding/development
1.11 1.40 1.56 1.13 1.26 1.77 highest
1.20 1.39 1.66 1.03 1.23 1.71 highest
1.23 1.20
1.29 1.21
1.31 1.20
1.32 1.29
1.34 1.29
1.38 1.30
1.30 1.38
1.52 1.29
1.36 1.52
1.35 1.66
0.65 4.13
1.47
1.56
1.57
1.70
1.73
1.80
1.80
1.96
2.07
2.24
2.67
0.88
0.90
0.89
0.90
0.86
0.88
1.13
0.85
0.94
1.06
1.01
1.08
1.16
1.16
1.18
1.15
1.22
1.47
1.29
1.28
1.43
0.66
1.30
1.40
1.39
1.53
1.48
1.59
2.03
1.67
1.94
2.37
2.71
high
high
high
high
high
high
high
high
high
high
high
0.51 6.82 3.49 0.87 0.45 3.05 high
1.37 3.96 5.40 1.12 1.53 6.07 high
rcA1 37583_at
U82612cdsat
rcAA817854_s_at
M81183ExonUTR_gat
D00698_s_at
L11007_at
AB005540_at
AJ000557cds_s_at
rc_Al231213_g_at
X03015_at
rcAA893579_at
rcAA799711_at
rc_A1059508_s_at
S59158_at
U09401_s_at
A1137583
U82612
AA817854
M81183
D00698
L11007
AB005540
AJ000557
A1231213
X03015
AA893579
AA79971 1
A1059508
S59158
U09401
1.60
2.97
1.65
1.89
1.79
1.59
1.67
1.62
1.73
1.85
2.20
1.69
1.92
2.00
6.39
0.77
0.42
0.76
0.67
0.72
0.82
0.79
0.82
0.77
0.74
0.63
0.83
0.74
0.71
0.22
1.23
1.24
1.25
1.26
1.30
1.31
1.33
1.33
1.33
1.36
1.38
1.40
1.42
1.42
1.43
1.17
1.00
1.01
1.00
0.98
0.94
1.01
0.91
1.12
1.07
1.00
0.86
0.96
1.13
1.00
1.86
2.96
1.66
1.90
1.76
1.49
1.69
1.47
1.94
1.97
2.20
1.46
1.84
2.26
6.39
1.43 lower
1.23 lower
1.26 lower
1.26 lower
1.27 lower
1.23 lower
1.34 lower
1.20 lower
1.49 lower
1.45 lower
1.38 lower
1.20 lower
1.36 lower
1.61 lower
1.43 lower
U21662_at
rc_A1231778_at
ABO1 7596_at
U77829mRNA_s_at
rc_A070295_g_at
rcAA899253_at
J05132_s_at
Y12009_at
S77494_s_at
rcAA866454_at
L32591 mRNAg-at
rcAA926129_at
L07114_at
M10072mRNA_s_at
rcAA875620_at
AF087943_s at
L32591mRNAat
rcAA859827_at
rcAA891725_at
AJ223184_at
X04139_s_at
K03039mRNA_s_at
M34253_at
U82612cds_g_at
L00191cds#1_s_at
M34253_g_at
X83537_at
M32062_g_at
rcAA891944_at
J05495_at
S66184_s_at
U21662
A1231778
ABO17596
U77829
A1070295
AA899253
J05132
Y12009
S77494
AA866454
L32591
AA926129
L07114
M1 0072
AA875620
AF087943
L32591
AA859827
AA891725
AJ223184
X04139
K03039
M34253
U82612
L00191
M34253
X83537
M32062
AA891944
J05495
S66184
fn-1: fibronectin cell adhesion/cell migration/ECM/cell
cycle/development
collagen and elastin
crosslinking/ECM/tumor suppressor
U _73 _~tU73553 .6 40 .1 .1 47 oe
1.99
1.84
2.07
1.94
2.77
1.91
1.92
2.15
3.37
3.02
2.33
2.31
2.41
2.48
2.32
2.68
2.64
2.76
2.62
3.73
2.73
2.99
3.03
5.27
0.73
0.80
0.71
0.77
0.55
0.80
0.79
0.76
0.49
0.55
0.72
0.76
0.75
0.75
0.80
0.70
0.74
0.71
0.79
0.57
0.83
0.75
0.76
0.46
1.46
1.48
1.48
1.49
1.52
1.52
1.53
1.62
1.64
1.66
1.67
1.76
1.80
1.85
1.85
1.87
1.96
1.97
2.07
2.14
2.25
2.26
2.31
2.40
2.50
2.77
2.95
3.04
3.09
3.20
3.77
1.10
0.88
0.86
0.98
0.98
0.87
1.11
1.08
1.19
1.00
0.90
1.15
1.14
0.96
0.85
0.91
0.86
0.87
0.90
1.14
1.19
1.00
1.19
0.85
0.94
0.96
0.96
1.07
0.93
0.85
1.00
2.18
1.62
1.78
1.91
2.71
1.66
2.14
2.31
4.01
3.01
2.10
2.65
2.76
2.37
1.96
2.43
2.26
2.41
2.35
4.24
3.24
2.99
3.62
4.46
4.19
3.52
3.71
4.09
3.81
3.37
10.17
1.60 lower
1.30 lower
1.27 lower
1.46 lower
1.49 lower
1.32 lower
1.70 lower
1.74 lower
1.95 lower
1.66 lower
1.51 lower
2.01 lower
2.06 lower
1.77 lower
1.57 lower
1.70 lower
1.68 lower
1.72 lower
1.86 lower
2.43 lower
2.67 lower
2.26 lower
2.76 lower
2.03 lower
2.35 lower
2.65 lower
2.84 lower
3.26 lower
2.88 lower
2.72 lower
3.77 lower
4.44 0.56
3.68 0.75
3.86 0.77
3.81 0.80
4.09 0.76
3.97 0.81
10.17 0.37
5.39 0.76 4.08 1.15 6.21 4.71 lowerU17035 s at U 17035
Table 1.2
Genes corresponding to Figure 5, profile 2
Probe Set Accession # Gene Function FV/F F$SV F F/NF FV/NF FS/NF Probability
rcAA799465_at
rc_A1233225_at
AA799465 unknown unknown
Al233225 Gucyl b3: guanylate cyclase 1, soluble, cGMP biosynthesis/nitric oxide signal
0.84 0.63 0.53 1.19 1.00 0.63 highest
0.84 0.70 0.58 1.16 0.97 0.68 highest
M77184_i at
rcA1639331_at
rc_A1009268_at
rcAA859896_at
X72757_at
X75785_at
rcA1638958_at
rcH31610_at
X89705cdsat
rc_A1639272_at
rcAA956941_at
rcAA892797_at
rcAA894297_at
rcAA874912_at
rcAA874857_at
rcAA799751_at
AJ224680_at
X89703cdsat
Y00766_g.at
beta 3
M77184 PTHR1: parathyroid hormone receptor
1
A1639331
A1009268
unknown
Camk2d: calcium/calmodulin-
dependent protein kinase 11, delta
AA859896 Marcks: myristoylated alanine rich
protein kinase C substrate
X72757 Cox6al: cytochrome c oxidase,
subunit Via, polypeptide 1
X75785 Sycp3: Synaptonemal complex protein
A1638958
H31610
X89705
A1639272
AA956941
3
unknown
unknown
Q1r606: olfactory receptor gene
Olr1 606
unknown
Tcf4: transcription factor 4
AA892797 Pgkl: phosphoglycerate kinase 1
AA894297 unknown
AA874912 similar to MOSPD1: motile sperm
domain containing 1
AA874857 similar to PURB: purine-rich element
binding protein B
AA799751 unknown
AJ224680
X89703
Y00766
Cngbl: cyclic nucleotide-gated
channel beta subunit 1
unknown
Scn3a: Sodium channel, voltage-
gated, type Ill, alpha polypeptide
transduction/vasodilation/circulation
Ca metabolism/Ca signaling/cell
cycle/G protein-coupled receptor
unknown
Ca-binding/serine/threonine protein
kinase/Ca-Calmodulin signal
transduction
actin crosslinking/cell cycle/binds to Ca
Calmodulin/cytoskeleton
energy production/mitochondrion
cell cycle
unknown
unknown
signal transduction/ 7 transmembrane
receptor
unknown
transcription factor/cell cycle
glycolysis/energy production
unknown
unknown
transcription factor/DNA replication/cell
cycle
unknown
Potassium channel cAMP gated
unknown
Na channel voltage gated/Ca-binding
1.10 0.55 0.61 0.96 1.07 0.59 highest
0.93 0.66 0.61 0.99 0.92 0.61 highest
0.88 0.73 0.64 1.10 0.96 0.71 highest
0.96 0.68 0.65 1.20 1.16 0.78 highest
0.99 0.67 0.66 1.17 1.16 0.78 highest
0.84 0.80 0.67 1.19 1.00 0.80 highest
1.04 0.66 0.69 1.03 1.07 0.71 highest
0.92 0.75 0.69 1.10 1.02 0.76 highest
0.86 0.81 0.69 1.08 0.93 0.75 highest
0.88
0.85
0.96
0.99
0.97
0.79
0.82
0.74
0.74
0.75
0.70
0.70
0.71
0.73
0.73
1.08
1.13
1.03
1.02
0.96
0.95
0.96
0.99
1.01
0.93
0.76 highest
0.79 highest
0.73 highest
0.74 highest
0.70 highest
0.92 0.80 0.73 1.06 0.97 0.78 highest
0.95 0.77 0.74 0.92 0.87 0.68 highest
0.98 0.76 0.74 0.98 0.97 0.73 highest
1.04 0.71 0.74 1.10 1.14 0.81 highest
0.92 0.81 0.75 0.90 0.83 0.67 highest
rc_A1009111_at
rcA1639209_at
rc_A1236145_at
rcAA799538_at
rcAA859994_at
rcA1639106_at
M23264_at
L12025_at
L29573_s_at
M13962mRNA#2_at
M29853_at
rcA1227715_at
rcAA892550_g_at
rcAA875496_at
rcAA892504_at
U32314_gat
rcAA849036_at
rcAA894104_at
K01677_at
rcAA891800_g9at
U10995_at
A10091 11 Psmal: proteasome (prosome,
macropain) subunit, alpha type 1
A1639209 unknown
A1236145 Hsdl7b7: hydroxysteroid
dehydrogenase 17 beta, type 7
AA799538 similar to SFRS2: splicing factor,
arginine/serine-rich 2
AA859994 similar to E. coli Beta-galactosidase
A1639106
M23264
LI 2025
L29573
unknown
Ar: androgen receptor
Taa1: tumor-associated antigen 1
SIc6a2: solute carrier family 6
(neurotransmitter
transporternoradrenalin), member 2
M13962 Gusb: Glucuronidase, beta
M29853 Cyp4bl: cytochrome P450, subfamily
4B, polypeptide 1
A1227715 Rbl2: retinoblastoma-like 2
AA892550 similar to FBXO22: F-box only protein
22
AA875496 unknown
AA892504 unknown
U32314 Pc: Pyruvate carboxylase
AA849036 Gucyla3: guanylate cyclase 1, soluble,
alpha 3
AA894104 unknown
K01677 Eif5: eukaryotic initiation factor 5 (elF-
5)
AA891800 unknown
U10995 Nr2fl: nuclear receptor subfamily 2,
protein catabolism
unknown
steroid/androgen biosynthesis
RNA splicing
carbohydrate metabolism
unknown
androgen activated transcription
factor/cell cycle/signal
transduction/receptor
unknown
norepinephrine transporter plasma
membrane
carbohydrate metabolism
drug and lipid metabolism including
steroids
transcritpion factor/cell cycle
ubiquitination
unknown
unknown
lipid
biosynthesis/gluconeogenesis/mitocho
ndrion
cGMP biosynthesis/nitric oxide signal
transduction/vasodilation/circulation
unknown
translation initiation
unknown
transcription factor/steroid hormone
0.92 0.82 0.75 0.98 0.90 0.73 highest
0.94 0.79 0.75 0.97 0.92 0.73 highest
0.98 0.77 0.75 1.01 0.99 0.76 highest
1.10 0.68 0.75 1.02 1.13 0.77 highest
0.95 0.79 0.75 1.01 0.97 0.76 highest
0.92 0.82 0.75 1.04 0.95 0.78 highest
1.03 0.74 0.76 0.94 0.97 0.71 highest
0.97 0.78 0.76 0.96 0.93 0.73 highest
0.98 0.78 0.76 1.04 1.02 0.79 highest
1.04 0.73 0.76 0.92 0.96 0.70 highest
0.97 0.79 0.76 0.90 0.87 0.69 highest
0.96 0.80 0.77 0.89 0.85 0.68 highest
1.00 0.79 0.79 1.05 1.05 0.83 highest
0.95 0.83 0.79 0.99 0.94 0.78 highest
1.02 0.79 0.80 0.98 0.99 0.78 highest
0.99 0.82 0.81 0.84 0.83 0.68 highest
0.99 0.83 0.82 0.99 0.98 0.81 highest
1.04 0.79 0.82 1.01 1.04 0.83 highest
1.16 0.71 0.83 0.92 1.07 0.76 highest
1.01 0.82 0.83 0.86 0.87 0.72 highest
1.13 0.74 0.83 0.99 1.12 0.82 highest
reetr/sianal trndcin
0.81 0.16 0.13 1.12 0.91 0.15 highrecentor/sianal transductionCa-binding/actin cytoskeletonrcA1639523_at A1639523
L19112_gat L19112 0.67 0.82 0.55 1.06 0.71 0.58 high
J00777_at J00777 0.72 0.77 0.55 1.00 0.72 0.56 high
L28818cdsat L28818 0.73 0.82 0.60 1.14 0.84 0.68 high
rcAA892400_at AA892400 0.83 0.73 0.60 1.08 0.89 0.64 high
U07619_at U07619 0.78 0.78 0.61 1.09 0.85 0.66 high
rcAA891721_at AA891721 0.79 0.78 0.61 0.90 0.71 0.55 high
rcAA892677_at AA892677 0.75 0.82 0.61 1.09 0.81 0.67 high
U07683_at U07683 0.76 0.83 0.63 1.07 0.81 0.67 high
D31838_at D31838 0.79 0.81 0.63 1.18 0.93 0.75 high
rc_A1030089_at A1030089 0.79 0.81 0.65 1.10 0.87 0.71 high
rcA1639379_at A1639379 0.83 0.80 0.66 1.00 0.82 0.66 high
L13445_at L13445 1.23 0.63 0.77 0.85 1.05 0.66 high
rcA1639470_g_at A1639470 0.52 1.35 0.70 1.18 0.61 0.82 lower
Table 1.3
Genes corresponding to Figure 5, Profile 3
Probe Set Accession # Gene Function FV/F FS/FV FSF F/NF FV/NF FS/NF Probability
rc_A014135_at A1014135 unknown unknown 1.10 0.64 0.71 2.80 3.07 1.98 highest
X05472cds#2_at X05472 unknown unknown 0.97 0.78 0.76 1.75 1.70 1.33 highest
rc_AI014135_g_at A1014135 unknown unknown 1.10 0.70 0.77 2.27 2.48 1.74 highest
rc_A1171962_s_at A1171962 Anxal: annexin 1 Ca-binding/inhibits phospholipase A2 0.96 0.81 0.78 2.22 2.14 1.73 highest
signal transduction/anti-
inflammatory/cell cycle
AF030091 UTR#1_g_at AF030091 Ccnl: cyclin L cell cycle 0.96 0.83 0.80 2.03 1.95 1.62 highest
rcAA799992_at AA799992 similar to C11 orfl 7: chromosome 11 unknown 1.00 0.80 0.80 2.39 2.39 1.92 highest
open reading frame 17
U1 7254_g_at U17254 0.36 0.57 0.20 6.99 2.50 1.41 high
rcAA800750_f at AA800750 unknown unknown 0.82 0.40 0.32 4.53 3.70 1.46 high
rc_A1178971_at Al178971 0.55 0.78 0.43 3.00 1.64 1.28 high
M24067_at M24067 0.61 0.79 0.48 2.87 1.75 1.38 high
AF055714UTR#1_at AF055714 0.79 0.66 0.53 3.72 2.95 1.96 high
D17309_at D17309 0.76 0.76 0.58 2.27 1.73 1.31 high
rcAA874848_sat AA874848 1.24 0.59 0.74 1.84 2.29 1.35 high
M18416_at M18416 0.09 1.74 0.15 20.71 1.81 3.14 lower
AF023087_s_at AF023087 0.17 1.22 0.21 15.31 2.68 3.27 lower
S74351_s_at S74351 0.18 1.22 0.22 7.48 1.38 1.68 lower
rcAA891041Iat AA891041 0.19 1.28 0.25 12.72 2.43 3.12 lower
rcAA944156_s_at AA944156 0.24 1.25 0.31 4.12 1.01 1.26 lower
X54686cdsat X54686 0.29 1.33 0.39 13.73 3.99 5.32 lower
X96437mRNA_g_at X96437 0.49 1.33 0.66 2.27 1.12 1.49 lower
D86297_at D86297 0.46 1.69 0.78 1.90 0.88 1.48 lower
Table 1.4
Genes corresponding to Figure 5, Profile 4
Probe Set Accession # Gene Function FV/F FS/FV FSF F/NF FV/NF FS/NF Probability
rcAA851223-at AA851223 Eno3: enolase 3, beta glycolysis/energy production 0.93 1.88 1.74 0.39 0.36 0.67 highest
AJ222724_at AJ222724 1.29 1.21 1.56 0.49 0.64 0.77 high
D89070cdssat D89070 1.28 1.35 1.72 0.46 0.59 0.79 high
rc_A1639162_at A1639162 1.37 1.30 1.77 0.40 0.55 0.71 high
U61184_at U61184 1.58 0.77 1.22 0.68 1.08 0.83 lower
rcAA817846_at AA817846 1.57 0.78 1.22 0.49 0.78 0.60 lower
U77931at U77931 1.58 0.78 1.24 0.62 0.98 0.77 lower
rcAA799406_at AA799406 1.74 0.72 1.24 0.52 0.91 0.65 lower
rcA1044488_at A1044488 1.92 0.66 1.26 0.63 1.21 0.79 lower
AB007689_at AB007689 1.54 0.83 1.28 0.62 0.95 0.79 lower
U31815_s_at U31815 1.68 0.76 1.28 0.64 1.07 0.82 lower
X66366_at X66366 1.71 0.75 1.29 0.56 0.96 0.72 lower
AF034577_at AF034577 2.25 0.58 1.30 0.51 1.16 0.67 lower
E03344cdssat E03344 1.65 0.79 1.30 0.58 0.95 0.75 lower
U36773_gat U36773 1.85 0.71 1.31 0.52 0.97 0.68 lower
rcH33528_at H33528 1.70 0.77 1.32 0.60 1.02 0.79 lower
rc_Al030286-s-at A1030286 1.97 0.67 1.33 0.50 0.99 0.67 lower
U83895_at U83895 1.63 0.83 1.36 0.53 0.86 0.72 lower
AF056333_s_at AF056333 2.34 0.59 1.37 0.48 1.11 0.65 lower
U35775_g_at U35775 1.77 0.79 1.39 0.59 1.04 0.82 lower
D14425_s_at D14425 1.90 0.74 1.40 0.50 0.95 0.70 lower
rcAA892339_at AA892339 1.78 0.80 1.43 0.50 0.89 0.71 lower
M31809_at M31809 1.88 0.76 1.43 0.52 0.97 0.74 lower
rcAA800763_at AA800763 1.83 0.79 1.44 0.52 0.96 0.75 lower
rcAA800768_at AA800768 1.73 0.83 1.44 0.47 0.81 0.68 lower
M93401_at M93401 1.80 0.81 1.45 0.49 0.88 0.71 lower
rcAA892500_at AA892500 1.91 0.76 1.46 0.55 1.04 0.80 lower
AF055286_g_at AF055286 1.83 0.80 1.47 0.37 0.68 0.54 lower
L29090cdsat L29090 1.78 0.83 1.47 0.45 0.81 0.67 lower
L13406_s_at L13406 1.86 0.79 1.47 0.43 0.81 0.64 lower
rcAA859982_at AA859982 2.05 0.72 1.48 0.53 1.09 0.78 lower
AF055286_at AF055286 2.00 0.75 1.49 0.44 0.88 0.66 lower
X13167cds_s_at X13167 2.17 0.72 1.57 0.52 1.13 0.81 lower
rcAA925887at AA925887 1.98 0.80 1.57 0.37 0.73 0.58 lower
rcAA893172_at AA893172 2.59 0.61 1.57 0.38 0.99 0.60 lower
D25233cds_at D25233 2.58 0.63 1.61 0.46 1.19 0.75 lower
M24104_at M24104 2.48 0.67 1.67 0.46 1.15 0.78 lower
rc_A1233261_i-at A1233261 2.39 0.73 1.75 0.40 0.94 0.69 lower
rcAA800912_g_at AA800912 2.43 0.72 1.76 0.42 1.02 0.74 lower
X99337cds_s_at X99337 2.46 0.74 1.82 0.45 1.11 0.83 lower
AF075382_at AF075382 2.35 0.80 1.87 0.39 0.91 0.73 lower
rcAA799637_g_at AA799637 2.79 0.70 1.95 0.33 0.93 0.65 lower
D84487_at D84487 2.63 0.76 2.01 0.35 0.92 0.70 lower
S90449_at S90449 2.77 0.83 2.29 0.35 0.96 0.79 lower
rcAA893242_g_at AA893242 3.36 0.68 2.30 0.25 0.82 0.56 lower
Y12517cdsat Y12517 3.19 0.77 2.44 0.25 0.81 0.62 lower
U95157_at U95157 3.51 0.77 2.70 0.29 1.01 0.78 lower
L13407_i at L13407 4.35 0.68 2.97 0.18 0.76 0.52 lower
Table 1.5
Genes corresponding to Figure 5, Profile 5
Probe Set Accession # Gene Function FV/F FS/PV FS F/NF FV/NF FS/NF Probability
S68245_g_at
X07636_at
AF104362_at
rc_A1639475_at
rcAA892228_at
rcAA925248-at
rcAA799472_at
AB003726_at
rcA1639060_at
M25804_at
rcAA858578_at
rcAA859545_at
Dl12769_g_at
X73653_at
AB008538_at
rcAA892637_at
U20796_at
rcAA799526_at
M23697_at
S68245
X07636
Ca4: carbonic anhydrase 4 respiration/acid-base balance
Asgr2: asialoglycoprotein receptor 2 cell surface receptor signal
transduction
AF104362 Omd: osteomodulin (osteoadherin)
A1639475 unknown
AA892228 similar to CUGBP1: CUG triplet repeat,
RNA binding protein 1
AA925248 Scn6a: sodium channel, voltage-gated,
type 6, alpha polypeptide
AA799472 unknown
AB003726 Homeri: homer, neuronal immediate
early gene, 1
A1639060 unknown
M25804 Nr1dl: nuclear receptor subfamily 1,
AA858578
AA859545
D1 2769
X73653
group D, member 1
unknown
unknown
KIf9: Kruppel-like factor 9
Gsk3b: glycogen synthase kinase 3
beta
AB008538 Alcam: activated leukocyte cell
adhesion molecule
AA892637 similar to GRP58: glucose regulated
protein, 58kDa
U20796 Nr1d2: nuclear receptor subfamily 1,
group D, member 2
AA799526 unknown
M23697 Plat: Plasminogen activator, tissue
rcA1639245_at A1639245 unknown
ECM/cell adhesion
unknown
mRNA processing/RNA
interference/development
Na channel voltage gated
unknown
regulates glutamate receptors
unknown
transcription factor/steroid hormone
receptor/myoblast
differentiation/development/triglyceride
metabolism/atherosclerosis
unknown
unknown
transcription factor
serine/threonine kinase/energy
metabolism/development/cell
cycle/signal transduction
signal transduction/cell
adhesion/immune response
protein modification/signal transduction
transcription factor/steroid hormone
receptor
unknown
blood coagulation/protease/cell
migration/tissue
remodeling/extracellular
unknown
0.91 0.64 0.58 1.46 1.33 0.85 highest
0.85 0.73 0.62 1.55 1.32 0.97 highest
0.90 0.71 0.64 1.47 1.33 0.94 highest
0.86 0.76 0.65 1.35 1.16 0.87 highest
0.84 0.82 0.69 1.37 1.15 0.94 highest
1.00 0.71 0.71 1.27 1.27 0.90 highest
0.86 0.83 0.71 1.46 1.26 1.04 highest
0.96 0.75 0.72 1.32 1.27 0.95 highest
0.98 0.74 0.72 1.38 1.35 1.00 highest
1.03 0.71 0.73 1.64 1.69 1.19 highest
0.92
0.91
0.97
0.99
0.80
0.82
0.77
0.76
0.74
0.75
0.75
0.76
1.56
1.28
1.24
1.33
1.44
1.16
1.20
1.32
1.16
0.96
0.92
1.01
highest
highest
highest
highest
1.07 0.71 0.76 1.23 1.32 0.93 highest
0.92 0.83 0.76 1.33 1.23 1.02 highest
0.99 0.78 0.77 1.25 1.24 0.97 highest
0.95 0.82 0.78 1.26 1.21 0.99 highest
1.03 0.76 0.79 1.50 1.55 1.19 highest
1.06 0.76 0.81 1.30 1.38 1.05 highest
rc_A1072435_at
U47110_at
A1072435 Nsepl: nuclease sensitive element transcription factor/cell cycle
binding protein 1
U471 10 Cask: calcium/calmodulin-dependent Ca-Calmodulin binding/signal
transduction/actin cytoskeleton/serine-
0.99 0.82 0.81 1.28 1.26 1.04 highest
1.16 0.72 0.83 1.26 1.46 1.04 highest
rcAA799459_at
rcAA800784_at
L26292_g_at
rcAA893260_at
AF096835_at
U17697_s_at
AF031657mRNA at
U75404UTR#1_s_at
rcAA866443_at
rcA1639412_at
rcAA893846_at
serine Drotein kinase threonine kinase
AA799459
AA800784
L26292
AA893260
AF096835
U17697 Cyp51: cytochrome P450, subfamily cholesterol/steroid biosynthesis
51
AF031657 zinc-finger protein 94 (Zfp94) gene transcription factor
U75404
AA866443
A1639412
AA893846
0.56 0.73
0.69 0.66
0.67 0.73
0.83 0.73
0.74 0.83
0.76 0.81
0.41
0.46
0.49
0.61
0.61
0.62
2.08
2.38
2.16
1.64
1.40
1.46
1.17
1.65
1.45
1.37
1.03
1.11
0.86 high
1.10 high
1.05 high
1.00 high
0.85 high
0.90 high
0.75 0.83 0.62 1.43 1.07 0.89 high
0.82
1.29
1.22
1.47
0.79
0.54
0.63
0.54
0.64
0.70
0.77
0.79
1.31
1.23
1.38
1.22
1.07
1.59
1.69
1.80
0.84 high
0.86 high
1.07 high
0.97 high
U17254_at U17254 0.12 1.26 0.15 7.62 0.92 1.16 lower
rcAA891943_at AA891943 0.65 1.26 0.82 1.27 0.82 1.03 lower
rcAA875633.at AA875633 0.68 1.21 0.82 1.25 0.85 1.03 lower
Table 1.6
Genes corresponding to Figure 5, Profile 6
Probe Set Accession # Gene Function FV/F FS/FV FS/F F/NF FV/NF FS/NF Probability
rcAA892560_at AA892560 unknown unknown 0.97 1.25 1.20 0.81 0.78 0.97 highest
rc_A1639507_at A1639507 unknown unknown 0.95 1.30 1.23 0.71 0.67 0.87 highest
rc_Al105044_at A1105044 similar to POLR3K: polymerase (RNA) subunit of RNA polymerase 1I1 0.92 1.33 1.23 0.83 0.76 1.02 highest
Ill (DNA directed) polypeptide K, 12.3 /synthesis of tRNA and small
kDa ribosomal RNA
U46034_at U46034 Mmp1 1: Matrix metalloproteinase 11 breakdown of 1.02 1.26 1.29 0.82 0.84 1.06 highest
ECM/remodelling/metastasis/develop
(stromelysin 3) ment/Ca-binding
D30040_at D30040 Aktl: v-akt murine thymoma viral anti-apoptosis/cell cycle/signal 1.09 1.21 1.32 0.71 0.78 0.94 highest
transduction/serine-threonine kinase/G
oncogene homolog 1 protein coupled receptor
rcAA874934_at AA874934 Doc2a Ca-binding/Ca-dependent exocytosis 1.12 1.22 1.36 0.81 0.90 1.10 highest
U26310_at U26310 Tns: tensin focal adhesions/SH2 signal 1.09 1.28 1.40 0.65 0.71 0.91 highest
transduction/crosslinks actin
cytoskeleton
U30485mRNA_s_at U30485 aspartyl-tRNA synthetase (DRS1) tRNA synthesis 1.12 1.28 1.43 0.66 0.74 0.94 highest
rcAA875132_at AA875132 TPM1: tropomyosin 1 (alpha) cytoskeleton/regulation of muscle 1.03 1.41 1.45 0.75 0.77 1.08 highest
contraction and heart rate/muscle
development/contractile apparatus
L19341_at L19341 Acvrl: activin type I receptor TGF-B/growth and differentiation 1.06 1.41 1.50 0.73 0.78 1.10 highest
factor/receptor serine-threonine
kinase/signal transduction
AF080568_at AF080568 Pcyt2: phosphate cytidylyltransferase phospholipid biosynthesis 1.15 1.32 1.52 0.71 0.82 1.08 highest
2, ethanolamine
rc_A1234969_s_at A1234969 1.23 1.22 1.50 0.65 0.79 0.97 high
AF014009_at AF014009 1.29 1.20 1.55 0.71 0.91 1.09 high
X65296cds_s_at X65296 1.24 1.30 1.61 0.61 0.76 0.99 high
AF027571_s_at AF027571 1.32 1.25 1.65 0.56 0.73 0.92 high
X55298_at X55298 1.36 1.21 1.65 0.70 0.95 1.15 high
LOI15_at L01115 1.35 1.30 1.76 0.53 0.72 0.93 high
rc_A1145680_s_at A1145680 1.51 1.20 1.82 0.59 0.90 1.08 high
X74402_at X74402 1.56 1.21 1.90 0.58 0.91 1.11 high
rcAA799497_g-at AA799497 1.61 1.29 2.07 0.54 0.87 1.13 high
S50461_s-at S50461 1.71 1.24 2.13 0.55 0.94 1.17 high
Z15123exon#5_s-at Z15123 1.24 1.72 2.13 0.46 0.57 0.99 high
rc_A1008131_s_at A1008131 1.31 1.82 2.37 0.39 0.50 0.91 high
Y08138_at Y08138 2.17 1.26 2.74 0.37 0.81 1.02 high
M74494_g_at M74494 2.35 1.23 2.88 0.41 0.96 1.18 high
X06827_gat X06827 2.72 1.30 3.53 0.31 0.85 1.10 high
rcAA892146_f at AA892146 unknown unknown 1.40 2.79 3.90 0.29 0.40 1.12 high
M91234_f at M91234 VL30 element (virus-like 30S) unknown 1.34 3.28 4.41 0.25 0.33 1.09 high
M20131cds_s_at M20131 1.62 0.75 1.21 0.81 1.31 0.98 lower
U39320_at U39320 1.75 0.69 1.21 0.73 1.27 0.88 lower
U27201_at U27201 1.47 0.83 1.22 0.78 1.15 0.95 lower
S62096_s_at S62096 1.82 0.67 1.22 0.70 1.28 0.86 lower
rcAA892813_s_at AA892813 1.72 0.71 1.22 0.70 1.21 0.86 lower
E13890cds_s_at E13890 1.51 0.81 1.23 0.82 1.24 1.01 lower
U76997_at U76997 1.57 0.79 1.23 0.80 1.26 0.99 lower
S35751_f at S35751 1.86 0.66 1.23 0.75 1.40 0.93 lower
Z34004exonat Z34004 1.53 0.81 1.23 0.74 1.13 0.91 lower
rc_A1013472_at A101 3472 1.53 0.81 1.23 0.71 1.08 0.87 lower
rcH31955_at H31955 1.76 0.71 1.25 0.75 1.32 0.94 lower
rcAA866240_i at AA866240 1.55 0.81 1.25 0.71 1.10 0.88 lower
U87306_at U87306 1.55 0.81 1.26 0.76 1.17 0.95 lower
rcAA866444_s_at AA866444 1.51 0.83 1.26 0.79 1.20 1.00 lower
S79214cdssat S79214 1.65 0.77 1.26 0.81 1.33 1.02 lower
U40188_at U40188 1.59 0.80 1.27 0.78 1.24 0.99 lower
rcAA800053_at AA800053 1.59 0.80 1.27 0.71 1.12 0.90 lower
X6295OmRNA f at X62950 2.27 0.56 1.28 0.69 1.56 0.88 lower
D83598_at D83598 1.57 0.82 1.28 0.83 1.29 1.06 lower
rc_A1180288_s_at A1180288 1.60 0.80 1.28 0.80 1.29 1.03 lower
M83567_s_at M83567 1.74 0.74 1.28 0.69 1.19 0.88 lower
rcAA998683_at AA998683 1.57 0.83 1.29 0.83 1.30 1.07 lower
U50842_at U50842 1.71 0.76 1.29 0.75 1.28 0.97 lower
M94557_s_at M94557 1.82 0.71 1.30 0.71 1.30 0.93 lower
D15069_sat D15069 2.07 0.63 1.30 0.81 1.67 1.05 lower
rcAA819643_at AA819643 1.61 0.81 1.30 0.70 1.13 0.91 lower
U78090_s_at U78090 1.61 0.82 1.32 0.73 1.18 0.96 lower
D14421_at D14421 1.62 0.82 1.32 0.71 1.15 0.94 lower
rc_A1235492_at A1235492 1.62 0.82 1.33 0.70 1.13 0.94 lower
rcAA893980_at AA893980 1.77 0.77 1.36 0.77 1.37 1.05 lower
rcAA892598_g_at AA892598 1.70 0.80 1.36 0.73 1.24 0.99 lower
rcAA891803_at AA891803 1.70 0.82 1.39 0.60 1.02 0.84 lower
rcAA893870_g_at AA893870 1.90 0.74 1.41 0.80 1.51 1.12 lower
rc_Al009141_at A1009141 1.92 0.74 1.43 0.62 1.19 0.88 lower
L19180_g_at L19180 1.74 0.83 1.44 0.64 1.11 0.92 lower
J03025_at J03025 1.92 0.75 1.45 0.60 1.14 0.86 lower
rcAA892394_g_at AA892394 1.77 0.82 1.46 0.64 1.14 0.94 lower
S79213_at S79213 1.78 0.82 1.46 0.66 1.18 0.96 lower
U77697 at U77697 1.89 0.77 1.46 0.81 1.54 1.19 lower
U97146_at U97146 1.90 0.77 1.46 0.72 1.36 1.05 lower
X61296cds#2 f at X61296 2.10 0.70 1.47 0.69 1.44 1.01 lower
D25543_at D25543 1.80 0.82 1.47 0.68 1.22 0.99 lower
rc AA894312 at AA894312 2.02 0.73 1.47 0.79 1.59 1.16 lower
U09229 at U09229 1.80 0.82 1.47 0.69 1.24 1.01 lower
rc_A1229637_at A1229637 1.98 0.75 1.48 0.79 1.56 1.17 lower
ABO17655 s at ABO17655 1.83 0.81 1.49 0.65 1.18 0.96 lower
AB017912_g_at AB017912 1.88 0.80 1.50 0.80 1.51 1.20 lower
rcAA858626_at AA858626 1.89 0.81 1.54 0.73 1.38 1.12 lower
Z14118cds_g_at Z14118 2.08 0.74 1.54 0.72 1.49 1.10 lower
U32575 at U32575 2.01 0.78 1.57 0.62 1.25 0.98 lower
AA686579 at AA686579 2.23 0.72 1.60 0.65 1.45 1.04 lower
U90888 at U90888 2.50 0.65 1.63 0.62 1.54 1.00 lower
U15550 at U15550 2.50 0.65 1.63 0.66 1.64 1.07 lower
AF059678 s at AF059678 2.13 0.77 1.63 0.56 1.20 0.92 lower
J02998 at J02998 2.16 0.76 1.64 0.63 1.36 1.04 lower
rcA1639343_at A1639343 2.58 0.64 1.65 0.52 1.33 0.85 lower
U64030 at U64030 2.01 0.82 1.65 0.61 1.23 1.01 lower
U87971_g at U87971 2.26 0.74 1.68 0.70 1.59 1.18 lower
rcAA875506_at AA875506 2.31 0.74 1.70 0.66 1.51 1.11 lower
U91847 s at U91847 2.09 0.82 1.71 0.61 1.27 1.04 lower
U42755 at U42755 2.17 0.81 1.76 0.48 1.04 0.85 lower
D10754 at D10754 2.24 0.80 1.78 0.55 1.23 0.98 lower
S56464mRNA at S56464 2.27 0.78 1.78 0.59 1.34 1.05 lower
L15354 s at L15354 2.61 0.69 1.80 0.58 1.51 1.04 lower
S81497 s at S81497 2.33 0.80 1.86 0.57 1.33 1.06 lower
U13895_s_at U13895 2.68 0.70 1.87 0.45 1.21 0.84 lower
AF084205_at AF084205 2.29 0.82 1.88 0.58 1.32 1.09 lower
rc_A1014091_at A1014091 2.54 0.74 1.88 0.62 1.57 1.17 lower
D10938exon_s_at D10938 2.37 0.80 1.91 0.54 1.28 1.03 lower
rcAA800908_at AA800908 2.38 0.80 1.91 0.48 1.14 0.91 lower
Y09333_g_at Y09333 2.43 0.82 2.00 0.44 1.08 0.89 lower
AF087839mRNA#2_f at AF087839 2.85 0.70 2.01 0.50 1.42 1.00 lower
M58287_s_at M58287 2.61 0.79 2.05 0.45 1.18 0.93 lower
AF021935_at AF021935 2.55 0.81 2.07 0.51 1.30 1.05 lower
L04760_at L04760 2.77 0.80 2.21 0.44 1.23 0.98 lower
rc_A1233365-at A1233365 3.03 0.80 2.43 0.45 1.36 1.09 lower
rc_A1231354_at A1231354 3.40 0.74 2.52 0.37 1.27 0.94 lower
J03481mRNAat J03481 3.15 0.81 2.56 0.35 1.11 0.90 lower
AF099093_g_at AF099093 3.31 0.81 2.68 0.33 1.09 0.88 lower
AJ007632_s_at AJ007632 3.65 0.75 2.74 0.37 1.35 1.02 lower
U31599_at U31599 3.91 0.74 2.88 0.39 1.54 1.14 lower
AF061242_sat AF061242 3.61 0.82 2.95 0.31 1.10 0.90 lower
Y09333_at Y09333 6.61 0.79 5.21 0.17 1.11 0.87 lower
Table 1.7
Genes corresponding to Figure 5, Profile 7
Probe Set Accession # Gene Function FV/F FS/FV FS/F F/NF FV/NF FS/NF Probability
AF031430_at AF031430 Stx7: syntaxin 7 intracellular protein transport 1.11 0.58 0.64 1.25 1.39 0.81 highest
rcAA800708_at AA800708 unknown unknown 0.87 0.77 0.67 1.24 1.08 0.83 highest
rcA1169756_s_at Al169756 0.22 0.80 0.18 4.33 0.97 0.78 high
rcA1639394_at A1639394 0.68 0.73 0.50 1.47 1.00 0.73 high
J03179_g_at J03179 0.66 0.82 0.54 1.47 0.97 0.80 high
rcA1638984_at A1638984 0.74 0.74 0.54 1.23 0.90 0.67 high
AF000901_s_at AF000901 0.83 0.70 0.58 1.36 1.13 0.79 high
rcAA893043_at AA893043 0.76 0.77 0.59 1.31 1.00 0.78 high
rc_A1228675_at A1228675 0.75 0.79 0.59 1.26 0.94 0.75 high
J02589mRNA#2_at J02589 0.78 0.79 0.62 1.26 0.98 0.77 high
U34843_g_at U34843 0.82 0.76 0.62 1.23 1.01 0.77 high
U90312_at U90312 0.80 0.80 0.64 1.24 0.99 0.79 high
rcAA894086_gat AA894086 0.79 0.81 0.64 1.24 0.98 0.79 high
AF082834_s_at AF082834 0.51 1.22 0.62 1.24 0.63 0.76 lower
Table 1.8
Genes corresponding to Figure 5, Profile 8
Probe Set Accession # Gene Function FV/F FS/FV FS/F F/NF FV/NF FS/NF Probability
rcA1011376_at A1011376 1.36 1.24 1.69 0.77 1.05 1.30 high
U83883_at U83883 1.45 1.23 1.78 0.68 0.98 1.21 high
S53987_at S53987 1.42 1.39 1.97 0.67 0.95 1.32 high
M65251_sat M65251 1.71 1.22 2.09 0.72 1.24 1.51 high
rcAA875500_at AA875500 1.28 1.69 2.17 0.81 1.03 1.75 high
X51531cds.g-at X51531 atrial myosin light chai1 myosin/Ca-binding/muscle 0.73 3.06 2.23 0.74 0.54 1.66 high
contraction/cytoskeleton/heart
L26525_at L26525 1.62 1.38 2.24 0.56 0.91 1.25 high
D26154cdsat D26154 1.86 1.21 2.25 0.63 1.18 1.42 high
rc_A1008836_s_at A1008836 1.87 1.23 2.29 0.76 1.43 1.75 high
M96601_at M96601 2.17 1.22 2.64 0.64 1.40 1.70 high
M86870_at M86870 3.32 1.22 4.04 0.33 1.10 1.34 high
rcAA894027_at AA894027 5.77 1.58 9.09 0.21 1.22 1.92 high
X62951mRNA_s_at X62951 RNPBUS19, pBUS19 unknown 1.76 6.42 11.28 0.15 0.26 1.64 high
rc_Al230228_at Al230228 1.90 0.77 1.47 0.82 1.56 1.20 lower
rcAA892630_at AA892630 2.13 0.77 1.63 0.75 1.59 1.22 lower
D13623_g_at D13623 2.14 0.78 1.67 0.81 1.72 1.35 lower
rcAA800930_at AA800930 2.06 0.83 1.71 0.75 1.54 1.28 lower
U06434_at U06434 2.39 0.72 1.73 0.79 1.89 1.36 lower
AF065387_g_at AF065387 2.45 0.73 1.79 0.76 1.87 1.36 lower
S56937_s_at S56937 2.76 0.65 1.80 0.71 1.97 1.28 lower
S68135_s_at S68135 2.88 0.63 1.81 0.70 2.03 1.28 lower
Y09507_at Y09507 2.39 0.78 1.86 0.76 1.81 1.41 lower
rcAA925762_at AA925762 3.14 0.61 1.90 0.74 2.33 1.41 lower
rc_A1179610_at Al179610 3.84 0.50 1.92 0.66 2.52 1.26 lower
D30649mRNA_s_at D30649 2.63 0.76 1.99 0.83 2.17 1.65 lower
AF087944mRNA_s_at AF087944 2.80 0.74 2.07 0.72 2.01 1.48 lower
U1 3396_g_at U13396 2.75 0.76 2.10 0.70 1.92 1.46 lower
X83579_at X83579 2.88 0.75 2.15 0.72 2.09 1.55 lower
M92059_s_at M92059 3.55 0.62 2.19 0.77 2.72 1.68 lower
AF052596_at AF052596 2.84 0.79 2.25 0.53 1.52 1.21 lower
rc_A1231354_g_at A1231354 3.13 0.74 2.31 0.53 1.66 1.22 lower
U93306_at
D42145_at
AB006881mRNAat
rc_A1104012_at
AF100470_at
X64403_at
U31599_g_at
M14656_at
M10094_g_at
X53054_at
M31038_at
Z78279_g_at
M80367_at
J02722cdsat
U93306
D42145
AB006881
A1104012
AF100470
X64403
U31599
M14656
M10094
X53054
M31038
Z78279
M80367
J02722 Hmoxl: Heme oxygenase
3.80
3.04
3.01
3.32
3.42
3.67
3.80
3.95
6.26
6.94
7.18
9.32
10.24
heme catabolism/cell cycle/signal
transduction/cell survival
0.61
0.80
0.82
0.81
0.82
0.76
0.75
0.81
0.65
0.61
0.77
0.65
0.75
2.33
2.44
2.47
2.69
2.79
2.80
2.86
3.21
4.07
4.24
5.52
6.08
7.70
0.53
0.53
0.50
0.52
0.48
0.49
0.46
0.74
0.42
0.81
0.57
0.66
0.78
2.02
1.61
1.51
1.74
1.64
1.78
1.76
2.91
2.63
5.62
4.07
6.13
8.02
21.27 0.40 8.54 0.18 3.89
1.24 lower
1.29 lower
1.24 lower
1.41 lower
1.34 lower
1.36 lower
1.33 lower
2.36 lower
1.71 lower
3.43 lower
3.13 lower
4.00 lower
6.03 lower
1.56 lower
Table 1.9
Genes corresponding to Figure 5, Profile 9
Probe Set Accession # Gene Function FV/F F F I F/NF FV/NF FS/NF Probability
S65355_at S65355 Ednrb: endothelin receptor type B signal transduction/G protein coupled 0.93 1.32 1.23 1.23 1.14 1.51 highest
receptor/Ca-signaling/vasoactive/cel
cycle/development/ECM
AB005143_s_at AB005143 Ucp2: Uncoupling protein 2, energy homeostasis/mitochondrial/Ca 1.03 1.25 1.29 1.29 1.33 1.66 highest
mitochondrial
X14221_at X14221 Sftpc: Surfactant, pulmonary- lung surfactant for gas exchange 0.93 1.43 1.33 1.43 1.33 1.90 highest
associated protein C
L23128_g_at L23128 RT1-N1: RTI class lb gene, H2-TL- MHC Class I/growth 1.06 1.43 1.51 1.33 1.40 2.01 highest
like, grc region control/development
X89963_at X89963 Thbs4: thrombospondin 4 cell adhesion/cell motility/Ca- 1.10 1.40 1.54 1.61 1.78 2.48 highest
binding/development
U44948_at U44948 Csrp2: cysteine rich protein 2 myoblast 1.15 1.57 1.81 1.61 1.84 2.90 highest
differentiation/development/signal
transduction
X51529_at X51529 Pla2g2a: phospholipase A2, group IIA Ca-binding/Ca-dependant 1.15 1.77 2.05 1.74 2.01 3.57 highest
phospholipase A2 signaling activity/cell
(platelets, synovial fluid) cycle
X53858_at X53858 0.80 1.65 1.33 1.33 1.07 1.77 high
M84488_at M84488 1.35 1.45 1.96 2.63 3.56 5.17 high
L18948_at L18948 1.40 1.70 2.39 5.01 7.03 11.95 high
D64045_s_at D64045 1.55 1.84 2.84 1.65 2.55 4.68 high
rcAA957003_at AA957003 1.76 1.72 3.02 1.43 2.51 4.33 high
U42719_at U42719 2.17 1.40 3.03 1.45 3.15 4.41 high
U09256_at U09256 1.49 0.81 1.21 1.23 1.84 1.49 lower
U77038_g_at U77038 1.58 0.78 1.24 1.24 1.97 1.54 lower
X52711_at X52711 1.66 0.76 1.27 1.28 2.13 1.63 lower
M98820_at M98820 1.67 0.76 1.27 1.69 2.82 2.15 lower
D85189_at D85189 1.90 0.68 1.29 1.22 2.32 1.58 lower
S82383_s_at S82383 1.58 0.83 1.31 1.60 2.52 2.09 lower
AJ005394_at AJ005394 1.58 0.83 1.31 1.25 1.97 1.64 lower
M58364_at M58364 1.67 0.79 1.32 1.24 2.07 1.64 lower
S79676_s_at S79676 1.97 0.68 1.34 1.25 2.46 1.68 lower
X17053cds_s_at X17053 1.80 0.76 1.37 1.61 2.90 2.21 lower
AF029240_at
rc_A1237535_s_at
rc_A1070295_at
rcAA799861_g_at
rcAA799861_at
U28938_at
X1 7053mRNA_s_at
rcAA875531_s_at
X06916_at
U57362_at
rcA1639103_s_at
S76779_s_at
rc_A1179399_at
U14647_at
J02962_at
X05834_at
rc_A1231472_s_at
rcAA894029_at
U10894_s_at
AF050214_at
AJ222813_s_at
X57523_.gat
rc_A169327_g_at
rcAA894092_at
Z78279_at
M98049_s_at
AF029240
A1237535
A1070295
AA799861
AA799861
U28938
X17053
AA875531
X06916
U57362
A1639103
S76779
A1179399
U14647
J02962
X05834
A1231472
AA894029
U10894
AF050214
AJ222813
X57523
A1169327
AA894092
Z78279
M98049
Collal: collagen, type 1, alpha 1
1.87
1.75
2.17
2.94
2.66
1.84
2.03
2.25
1.91
2.86
2.16
2.30
2.66
2.47
2.64
3.33
3.19
2.87
3.01
4.20
3.24
4.74
4.97
7.02
collagen/ECM 10.89
9.54
0.74
0.82
0.67
0.51
0.57
0.82
0.75
0.69
0.83
0.56
0.77
0.73
0.66
0.82
0.78
0.64
0.70
0.80
0.76
0.59
0.79
0.67
0.74
0.56
0.49
0.66
1.37
1.44
1.46
1.50
1.50
1.51
1.52
1.54
1.58
1.60
1.66
1.68
1.75
2.03
2.06
2.15
2.24
2.30
2.30
2.46
2.56
3.18
3.67
3.90
5.29
6.26
1.30
1.27
1.27
1.96
2.85
1.33
2.46
1.58
2.20
1.68
1.85
1.36
1.33
1.21
1.46
1.82
1.84
1.27
1.52
1.45
1.52
1.57
2.52
4.79
1.46
3.30
2.42
2.24
2.76
5.78
7.58
2.44
4.99
3.55
4.20
4.81
4.00
3.14
3.54
2.98
3.85
6.07
5.87
3.64
4.57
6.10
4.94
7.42
12.55
33.63
15.90
31.45
1.78 lower
1.84 lower
1.86 lower
2.94 lower
4.29 lower
2.00 lower
3.74 lower
2.44 lower
3.49 lower
2.69 lower
3.07 lower
2.29 lower
2.33 lower
2.45 lower
3.01 lower
3.91 lower
4.13 lower
2.92 lower
3.49 lower
3.57 lower
3.90 lower
4.98 lower
9.26 lower
18.70 lower
7.73 lower
20.64 lower
Table 1.10
Genes corresponding to Figure 5, Profile 10
Probe Set Accession # Gene Function FV/F FS1EV ES/F F/NF FV/NF FS/NF Probability
rcAA891839_at AA891839 unknown unknown 0.84 0.70 0.59 0.76 0.64 0.45 highest
rc_A1233219_at A1233219 Esm1: endothelial cell-specific growth factor 0.89 0.78 0.70 0.75 0.67 0.52 highest
molecule 1
U14950_at U14950 DIgh1: discs, large homolog 1 cytoskeleton/guanylate kinase 0.97 0.74 0.72 0.76 0.74 0.55 highest
(Drosophila)
rcA1638988_at A1638988 unknown unknown 1.00 0.77 0.77 0.79 0.79 0.61 highest
rcAA892863_at AA892863 similar to hs MTCH2: mitochondrial transport 1.09 0.74 0.81 0.80 0.87 0.65 highest
carrier homolog 2 (C. elegans)
rcAA799656_at AA799656 similar to MRPS31: mitochondrial ribosome/mitochondrion 1.03 0.79 0.82 0.83 0.86 0.68 highest
ribosomal protein S31
U92564_g-at U92564 1.61 0.50 0.80 0.74 1.19 0.59 high
Table 2:
This is a list of all the 226 candidate gene for encoding natural adaptive responses to aortic
banding that are needed for clinical non-failure. Those genes correspond to the genes depicted in
Figure 6. The different fold changes that were used in the analysis are also found in the table.
Genes were ordered according to F/NF fold change. Genes were this fold change is < 0.5 or > 2
are shaded in gray.
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Table 2.1
Genes corresponding to Figure 6, Profile 1
Probe Set Accession # Gene Function FV/F FS/FV FS/F FINF FV/NF FS/NF
rcAA818982_at
rcAA799883_at
rcAA893160_at
J02827_at
AB009999_g_at
Z49858_at
AF062740_g_at
X06889cdsat
M84719_at
rcAA859508_at
AJ001320_at
rcAA891499_at
rcAA892280_at
rcAA891962_at
D82074_at
rcAA891069_at
L15618_at
rcAA859975_at
rc_A1231547_at
U22830_at
rcAA799421_at
AA818982
AA799883
AA893160
J02827
Tmpo: thymopoietin
unknown
unknown
Bckdha: branched chain keto acid
dehydrogenase subunit El, alpha polypeptide
AB009999 Cds1: CDP-diacylglycerol synthase
(phosphatidate cytidylyltransferase) 1
Z49858 TM4SF1 1: transmembrane 4 superfamily
member 11 (plasmolipin)
AF062740 PDPI: pyruvate dehydrogenase phosphatase
isoenzyme 1
X06889 RAB3A: RAB3A, member RAS oncogene
family
M84719 Fmol: flavin containing monooxygenase 1
AA859508
AJO01320
AA891499
AA892280
AA891962
D82074
unknown
Mpdz: multiple PDZ domain protein
unknown
unknown
unknown
NEURODI: neurogenic differentiation 1
AA891069 similar to SRPK2: SFRS protein kinase 2
LI 5618 CSNK2A1: casein kinase 2, alpha 1
polypeptide
AA859975 SLC25A1 1: solute carrier family 25
(mitochondrial carrier; oxoglutarate carrier),
member 11
A1231547 Fkbp4: FK506 binding protein 4
U22830 P2RY1: purinergic receptor P2Y, G-protein
coupled, 1
AA799421 PRKCE: protein kinase C, epsilon
DNA binding/transcription/cell cycle
unknown
unknown
keto acid metabolism/energy
1.14
1.05
0.97
1.14
production/mitochondrion
lipid metabolism/signal transduction/Ca-
signaling/mitochondrion+ER
ion channel
signal transduction/carbohydrate
metabolism/energy production
GTPase signal transduction/oncogene
oxidation of amino-trimethylamine
unknown
unknown
unknown
unknown
unknown
transcription factor/differentiation/insulin
transcription/development
serine-threonine kinase/signal transduction
serine-threonine kinase/signal transduction/cell
cycle
oxoglutarate carrier/energy
production/mitochondrion
protein folding/steroid receptor
trafficking/immunoregulation/Hsp binding/cell
cycle
signal transduction/G-protein receptor for ATP-
ADP/Ca-signaling/platelets
signal transduction/apoptosis/kinase
0.88
0.97
1.12
0.88
1.00
1.02
1.09
1.00
0.51
0.57
0.57
0.58
1.08 1.04 1.12 0.61
1.06 0.84 0.89 0.62
1.18 1.00 1.18 0.63
1.02 1.02 1.04 0.64
1.12 1.07
1.14 0.92
1.09 0.95
1.10 1.06
1.13 1.02
1.16 0.94
1.12 0.86
1.19
1.05
1.04
1.16
1.15
1.09
0.96
0.66
0.66
0.66
0.66
0.66
0.67
0.67
1.17 1.00 1.16 0.67
1.04 1.05 1.09 0.68
1.16 1.02 1.18 0.68
1.05 1.11 1.17 0.68
0.96 0.98 0.94 0.69
1.17 0.84 0.98 0.69 0.81 0.68
0.58
0.60
0.56
0.66
0.51
0.58
0.63
0.58
0.66 0.68
0.66 0.56
0.75 0.75
0.65 0.66
0.74
0.75
0.72
0.73
0.75
0.77
0.74
0.78
0.69
0.69
0.77
0.76
0.73
0.64
0.78 0.78
0.70 0.74
0.79 0.80
0.72 0.80
0.66 0.64
rcAA800036_at
rcAA892799_s_at
U68417_at
rcA1639155_at
rcAA875023_at
U10357_at
rcA1102838_s at
rcAA800120_at
rcAA892271_at
rc_A1228548_at
rcAA891037_g_at
rcH31982_at
D90109_at
U26356mRNA_s_at
rcAA875428_at
rc_AI044900_s_at
rcAA892821_at
L00370cds_s_at
rcAA859788_at
rcAA800275_at
U16802_at
AA800036
AA892799
U68417
A1639155
AA875023
U10357
A1102838
AA800120
AA892271
A1228548
AA891037
H31982
D90109
U26356
AA875428
A1044900
AA892821
L00370
AA859788
AA800275
U16802
similar to SCHIP1: schwannomin interacting
protein 1
similar to GRHPR: glyoxylate
red uctase/hydroxypyruvate reductase
BCAT2: branched chain aminotransferase 2,
mitochondrial
similar to C20orf36: chromosome 20 open
reading frame 36
unknown
PDK2: pyruvate dehydrogenase kinase,
isoenzyme 2
IVD: isovaleryl Coenzyme A dehydrogenase
SLC25A20: solute carrier family 25
(carnitine/acylcarnitine translocase), member
20
unknown
S10OA1: S100 calcium binding protein Al
similar to RPL3L: ribosomal protein L3-like
similar to ELAVL1: ELAV (embryonic lethal,
abnormal vision, Drosophila)-like 1 (Hu antigen
R)
ACSL1: acyl-CoA synthetase long-chain family
member 1
S10OA1: S100 calcium binding protein Al
similar to TCTA: T-cell leukemia translocation
altered gene
ACSL1: acyl-CoA synthetase long-chain family
member 1
AKR7A2: aldo-keto reductase family 7,
member A2 (aflatoxin aldehyde reductase)
embryonic skeletal muscle myosin heavy chain
gene
similar to MRPS1 1: mitochondrial ribosomal
protein S11
unknown
CADPS: Ca2+-dependent activator protein for
secretion
cytoskeleton
metabolism/energy production
amino acid metabolism/mitochondrion
protein modification
unknown
signal transduction/glucose metabolism/energy
prod uction/mitochondrion
amino acid catabolism/energy
production/mitochondrion
fatty acid transport for oxidation/energy
production/mitochondrion
unknown
Ca-binding/Ca-induced Ca release/cell
cycle/intracellular signaling
ribosome/specific to heart and muscle
mRNA catabolism/cell cycle/renin production
fatty acid metabolism/energy production
Ca-binding/Ca-induced Ca release/cell
cycle/intracellular signaling
unknown
fatty acid metabolism/energy production
carbohydrate metabolism/detoxification/energy
production
myosin/cytoskeleton/muscle/development
ribosome/mitochondrion
unknown
Ca-binding/exocytosis
1.14
1.08
1.15
1.13
1.07
1.19
1.03
0.92
0.95
0.99
0.94
0.94
1.18
1.00
1.09
1.12
1.00
1.13
0.69
0.70
0.70
0.71
0.71
0.71
1.19 0.97 1.16 0.71
1.13 0.99 1.12 0.71
1.18
1.11
1.04
1.13
1.05
1.03
1.03
1.08
1.05
1.00
1.13
1.10
1.09
0.88
0.87
0.96
0.97
0.96
1.07
1.03
1.00
0.97
1.00
0.99
0.88
0.90
1.03
0.96
1.00
1.10
1.01
1.11
1.06
1.08
1.02
1.00
1.11
0.97
0.98
0.72
0.72
0.73
0.73
0.73
0.74
0.74
0.74
0.74
0.74
0.74
0.75
0.75
0.79
0.75
0.80
0.80
0.75
0.85
0.82
0.70
0.76
0.79
0.71
0.80
0.85 0.82
0.80 0.80
0.84
0.80
0.75
0.83
0.77
0.76
0.76
0.80
0.78
0.74
0.84
0.82
0.81
0.74
0.69
0.73
0.80
0.74
0.82
0.78
0.80
0.75
0.74
0.83
0.73
0.74
D28561_s_at D28561 SLC2A4: solute carrier family 2 (facilitated
glucose transporter), member 4
rcAA859468_at
D26439_at
V01216_at
rcAA891521_at
rcAA892808_at
D13376_at
rcAA892547_at
ABO12234_g_at
rc_A1232256_at
rcAA799779_g-at
rc_A1012275_at
AB015724_at
J05571_s_at
X05341_at
X16554_at
AF035943_at
rcAA799531_at
rcAA875129_at
rcAA891800_at
rc_A1638960_g_at
rcAA799804_at
L20427_at
rcAA891790_at
rcAA891524_at
AA859468
D26439
V01216
AA891521
AA892808
D13376
AA892547
ABO1 2234
A1232256
AA799779
A1012275
ABO15724
J05571
X05341
X1 6554
AF035943
AA799531
AA875129
AA891800
A1638960
AA799804
L20427
AA891790
AA891524
similar to SHB: SHB (Src homology 2 domain
containing) adaptor protein B
CD1 D: CD1 D antigen, d polypeptide
Orm1: orosomucoid 1
unknown
IDH3G: isocitrate dehydrogenase 3 (NAD+)
gamma
Aki: adenylate kinase 1
unknown
NFIX: nuclear factor l/X (CCAAT-binding
transcription factor)
CYB5-M: cytochrome b5 outer mitochondrial
membrane precursor
GNPAT: glyceronephosphate 0-acyltransferase
C5orf12: chromosome 5 open reading frame 12
CGI-63: nuclear receptor binding factor 1
MAT2A: methionine adenosyltransferase 11,
alpha
Acaa2: acetyl-Coenzyme A acyltransferase 2
(mitochondrial 3-oxoacyl-Coenzyme A thiolase)
PRPS1: phosphoribosyl pyrophosphate
synthetase 1
UCP3: uncoupling protein 3 (mitochondrial,
proton carrier)
similar to NS3TP1: HCV NS3-transactivated
protein 1
similar to ELP4: elongation protein 4 homolog
(S. cerevisiae)
unknown
unknown
unknown
Coq3: coenzyme q (ubiquinone) biosynthetic
enzyme 3
unknown
unknown
glucose transporter/insulin
SH3/SH2 adaptor protein/intracellular signaling
cascade/cell cycle
antigen presentation/immune response
acute phase reactant/inflammatroy response
unknown
aa metabolism/rate limiting step of TCA/energy
production/mitochondrion
ATP metabolism/cell cycle/protein kinase
unknown
transcription factor/DNA replication
steroid biosynthesis/mitochondria
fatty acid metabolism/development
unknown
transcription factor/energy production
one carbon compound metabolism
fatty acid catabolism/energy
production/mitochondria
amino acid and nucleotide metabolism
energy production/mitochondrion
amino acid metabolism
translation
unknown
unknown
unknown
one carbon compound metabolism
unknown
unknown
0.97 1.00 0.98 0.75 0.73 0.73
1.06
1.04
1.00
1.01
1.03
1.14
1.19
1.10
1.03
1.10
1.16
1.06
1.01
1.05
1.13
1.16
1.12
1.04
0.96
1.05
1.12
1.16
1.04
1.08
1.02
1.00
1.02
1.06
0.98
0.96
0.89
0.96
1.01
0.88
0.88
0.88
0.96
1.00
0.90
0.91
0.85
1.03
0.97
0.91
0.95
0.86
0.91
0.90
1.08
1.04
1.02
1.07
1.00
1.10
1.06
1.06
1.03
0.96
1.02
0.93
0.97
1.05
1.01
1.05
0.95
1.07
0.94
0.95
1.07
0.99
0.95
0.97
0.75
0.75
0.75
0.75
0.76
0.76
0.76
0.76
0.76
0.77
0.77
0.77
0.77
0.77
0.77
0.77
0.77
0.78
0.78
0.78
0.78
0.78
0.79
0.79
0.80
0.78
0.75
0.76
0.77
0.87
0.90
0.84
0.79
0.84
0.89
0.81
0.78
0.81
0.87
0.90
0.87
0.80
0.75
0.82
0.87
0.90
0.82
0.85
0.81
0.78
0.77
0.81
0.76
0.83
0.81
0.81
0.79
0.73
0.78
0.71
0.74
0.80
0.78
0.81
0.74
0.83
0.73
0.74
0.83
0.77
0.75
0.76
J03190_g_at
rcAA800745_at
rcAA799594_at
D37880_at
U53486mRNA_s_at
rc_A1639451_at
M75148_at
X74227cdsat
rcAA800184_at
rcAA799464_at
rcAA800210_at
X01785_at
rcAA799299_at
U95920_at
M25888_at
rcAA891311_at
X14265_at
AF071204_g_at
J02749_at
rcAA875198_at
rcAA874955_s at
M18467_at
U08976_at
J03190
AA800745
AA799594
D37880
U53486
A1639451
M75148
X74227
Alas1: aminolevulinic acid synthase 1
Alad: aminolevulinate, delta-, dehydratase
unknown
TYRO3: TYRO3 protein tyrosine kinase
corticotropin releasing factor receptor
unknown
KNS2: kinesin 2 60/7OkDa
ITPKB: inositol 1,4,5-trisphosphate 3-kinase B
AA800184 unknown
AA799464 TIMM8B: translocase of inner mitochondrial
membrane 8 homolog B (yeast)
AA800210 CSNK2A1: casein kinase 2, alpha 1
polypeptide
X01785 MOX2: antigen identified by monoclonal
antibody MRC OX-2
AA799299 similar to AK5: adenylate kinase 5
U95920 PCM1: pericentriolar material 1
M25888 PLP1: proteolipid protein 1 (Pelizaeus-
Merzbacher disease, spastic paraplegia 2,
uncomplicated)
AA891311 unknown
X14265 CALM3: calmodulin 3 (phosphorylase kinase,
delta)
AF071204 KITLG: KIT ligand
J02749 ACAA1: acetyl-Coenzyme A acyltransferase 1
AA875198
AA874955
M18467
(peroxisomal 3-oxoacyl-Coenzyme A thiolase)
unknown
CLTB: clathrin, light polypeptide (Lcb)
GOT2: glutamic-oxaloacetic transaminase 2,
mitochondrial (aspartate aminotransferase 2)
U08976 Ech1: enoyl coenzyme A hydratase 1
heme biosynthesis/mitochondrion
heme biosynthesis
unknown
signal transduction/receptor tyrosine kinase
response to stress/immune
response/development/cell cycle/G protein
coupled receptor/signal transduction
unknown
cytoskeleton/motor activity
signal transduction/Ca-Calmodulin
binding/kinase/IP3
unknown
protein translocase/mitochondrion
serine-threonine kinase/signal transduction/cell
cycle
cell surface immunoglobulin/immune response
nucleotide metabolism/kinase
transcription
myelination
unknown
Ca-Camodulin binding/kinase/signal
transduction
signal transduction/cell cycle/cell
migration/development/hematopoesis/growth
factor
fatty acid metabolism/energy production
unknown
Ca-binding/receptor-mediated endocytosis
amino acid metabolism/mitochondrion
fatty acid catabolism/energy
production/mitochondrion
0.85
1.09
1.02
0.97
1.18
0.89
0.97
1.01
1.01
0.98
0.99
0.98
0.79
0.79
0.79
0.79
1.16 0.89 1.03 0.79
0.67
0.86
0.81
0.77
0.80
0.77
0.79
0.78
0.92 0.82
0.91 1.03 0.93 0.80 0.72 0.75
0.90 1.09 0.97 0.80 0.72 0.78
1.05 0.94 0.99 0.80 0.84 0.79
1.11 0.86 0.95 0.80
1.07 0.84 0.90 0.80
1.13 0.89 1.01 0.81
1.11 0.93 1.03 0.81
0.89 0.76
0.86 0.73
0.91 0.81
0.90 0.83
1.05 0.94 0.99 0.81 0.85 0.80
1.05 0.97 1.02 0.81 0.85 0.83
0.94 0.95 0.90 0.81 0.76 0.73
0.96 0.92 0.88 0.82
1.01 0.99 1.01 0.82
1.03 0.95 0.98 0.82
1.11 0.87 0.96 0.82
0.78 0.72
0.83 0.82
0.84 0.80
0.91 0.79
1.06 0.91 0.96 0.82 0.87 0.79
0.92 0.96 0.88 0.82 0.75 0.72
1.07 0.94 1.00 0.82 0.88 0.83
1.04 0.97 1.01 0.82 0.86 0.83
M36074_at
rcAA891037_at
rcAA957961_at
rcAA799879_at
rcAA892380_at
rcAA891864_at
rcAA891802_at
M36074 NR3C2: nuclear receptor subfamily 3, group C, signal
transduction/hypertension/mineralocorticoid
steroid hormone receptor/sodium ion
member 2 homeostasis/transcription factor
AA891037 similar to RPL3L: ribosomal protein L3-like ribosome/muscle and heart
AA957961 D1SI55E: NRAS-related gene transcription factor/DNA binding/RNA
binding/development
AA799879 SYNGR1: synaptogyrin 1 Ca-binding/synaptic vesicles exocytosis
AA892380 unknown unknown
AA891864 similar to AGTPBP1: ATP/GTP binding protein amino acid metabolism
1
AA891802 similar to Cyhr1: cysteine and histidine rich 1 unknown
1.10 0.92 1.01 0.82 0.90 0.83
0.97 1.03 0.99 0.82
1.14 0.84 0.97 0.83
0.91 1.07
1.17 0.84
1.16 0.85
0.98 0.83
0.99 0.83
0.99 0.83
0.96 0.97 0.94 0.83 0.80 0.78
0.79 0.82
0.94 0.80
0.75 0.81
0.97 0.82
0.97 0.83
Table 2.2
Genes corresponding to Figure 6, Profile 2
FV/F FS/FV ES/F F/N FV/NF FS/NF
rcAA892578_at
U53855_at
rcAA799992_gat
rcAA799534-at
rcAA849769_g_at
rc_A1169104_at
X62952_at
rcAA799762_gat
J03627_at
D00688_s_at
rcA1136891_at
M58404_at
U42627_at
Y13714_at
rcAA893743_at
L26268_at
AF030091 UTR#1_at
L40362_f at
D 1341 7_g_at
rcAA800663_at
S45812_s_at
AA892578
U53855
AA799992
AA799534
AA849769
Al169104
X62952
Similar to Platelet factor 4 precursor (PF-4)
(CXCL4)
VIM: vimentin
AA799762 similar to chromosome 20 open reading frame
149
J03627 S10OA10: S100 calcium binding protein A10
(annexin 11 ligand, calpactin I, light polypeptide
(p 11))
D00688 MAOA: monoamine oxidase A
A1136891 ZFP36L1: zinc finger protein 36, C3H type-like
1
M58404 TMSB10: thymosin, beta 10
U42627 DUSP6: dual specificity phosphatase 6
Y13714 SPARC: secreted protein, acidic, cysteine-rich
(osteonectin)
AA893743 Pkia: Protein kinase inhibitor, alpha
L26268 BTG1: B-cell translocation gene 1, anti-
proliferative
AF030091 CCNL1: cyclin Li
L40362 RT1 -Aw2: RT1 class Ib, locus Aw2
D13417 HES1: hairy and enhancer of split 1,
(Drosophila)
AA800663 similar to XPO7 exportin 7
S45812 MAOA: monoamine oxidase A
unknown
vasodilator/inhibitor of platelet aggregation
unknown
unknown
Ca-binding/autoantigen
immune response/signaling/inhibitor of
angiogenesis/platelet activation
cytoskeleton
unknown
Ca-binding/cell cycle/differentiation/interacts
with K-channel
catecholamine catabolism/mitochondrion
transcription factor/regulates response to
growth factors
cytoskeleton
cell-cycle/apoptosis/differentiation/serine-
threonine phosphatase/targets MAP
kinase/targeted by angiotensin l/signal
trnasduction
Ca-binding/ECM synthesis/cell-shape/cell
cycle/collagen-binding/angiogenesis
kinase inhibitor/signal transduction
tumor suppressor/cell
cycle/angiogenesis/myoblast
differentiation/transcription factor
cell-cycle
MHC class I /immune response/antigen
presentation
transcription factor/development
nuclear transport
catecholamine catabolism/mitochondrion
0.97
0.93
0.95
1.03
0.89
1.03
0.96
1.10
0.92
0.93
1.09
0.92
0.92
1.02
0.88
0.96
0.97
0.95
2.04
1.99
1.99
1.98
1.96
1.92
0.91 0.98 0.89 1.87
1.06 0.97 1.03 1.83
1.07 0.94 1.01 1.83
1.04 0.93 0.96 1.72
0.95 1.01 0.96 1.67
1.04 0.93 0.97 1.64
0.91 1.07 0.97 1.64
0.90 1.09 0.99 1.63
0.91 0.97 0.89 1.62
0.85 1.10 0.93 1.60
1.03
1.07
0.92 0.95 1.59
0.97 1.04 1.59
1.08 0.91 0.98 1.59
0.94 0.90 0.85 1.59
1.04 0.98 1.02 1.57
Probe Set Accession # Gene Function
1.97
1.85
1.89
2.04
1.74
1.97
1.89
2.03
1.74
1.90
1.89
1.82
1.70 1.66
1.94 1.88
1.96 1.84
1.79 1.66
1.59 1.60
1.70 1.59
1.49 1.59
1.47 1.61
1.48 1.44
1.36 1.49
1.64 1.52
1.70 1.65
1.71 1.56
1.49 1.34
1.63 1.60
rc_A1234146_at
rcAA894259_at
L23148_at
D00913_g_at
rc_A1639246_at
rcAA799498_at
U04835_at
X04979_at
rcAA859837_g_at
U72660_at
Z24721_at
AF041066_at
X01118_at
rcAA891940_at
X61295cds_s_at
AF087037_g_at
rcAA892897_at
D28560_g_at
J02780_at
rcAA891880_at
X05566 i at
L25785_at
X16145_at
A1234146 CSRP1: cysteine and glycine-rich protein 1
AA894259 similar to 201011 0M21 Rik: RIKEN cDNA
2010110M21 gene
L23148 IDI: inhibitor of DNA binding 1, dominant
negative helix-loop-helix protein
D00913 ICAMI1: intercellular adhesion molecule 1
(CD54), human rhinovirus receptor
A1639246 similar to Xlkdl: extra cellular link domain-
containing 1
AA799498 NPPB: natriuretic peptide precursor B
U04835
X04979
AA859837
U72660
Z24721
Crem: cAMP responsive element modulator
APOE: apolipoprotein E
GDA: guanine deaminase
NINJ1: ninjurin 1
SOD3: superoxide dismutase 3, extracellular
AF041066 ANG: angiogenin, ribonuclease, RNase A
family, 5
X01 118 NPPA: natriuretic peptide precursor A
AA891940 Similar to Potentail helicase MOV-10
(LOC310756)
X61295 LI retroposon, ORF2 mRNA (partial)
AF087037 Btg3: B-cell translocation gene 3
AA892897 PLOD2: procollagen-lysine, 2-oxoglutarate 5-
dioxygenase (lysine hydroxylase) 2
D28560 ENPP2: ectonucleotide
pyrophosphatase/phosphodiesterase 2
(autotaxin)
J02780 TPM4: tropomyosin 4
AA891880 Tricarboxylate carrier-like protein
X05566 Mrlcb: myosin regulatory light chain
L25785 TSC22: transforming growth factor beta-
stimulated protein TSC-22
X16145 FUCA1: fucosidase, alpha-L- 1, tissue
transcription factor/differentiation/cell
growth/development
unknown
transcription factor/differentiation/cell
growth/senescence/cell cycle
intercellular adhesion molecule/binds integrin
receptor for cell adhesion
receptor signal transduction/blood
pressure/diuresis/natriuresis/vasoactive/negativ
e regulation of cell growth and angiogenesis
transcription factor/signal transduction
lipoprotein triglyceride catabolism
nucleic acid metabolism/development
cell adhesion/development/tissue regeneration
superoxide metabolism
potent angiogenesis factor/tRNA catabolism
with decreased protein production
blood pressure regulation
RNA processing/development
unknown
anti-proliferative/cell cycle
collagen metabolism
G protein coupled receptor signal
transduction/nucleotide metabolism
cytoskeleton/muscle development
cation transporter
myosin/Ca-binding/cytoskeleton
transcription factor
carbohydrate metabolism/glycosaminoglycan
catabolism
0.94 1.02 0.96 1.56
1.09 0.96 1.05 1.55
0.88 1.02 0.90 1.55
1.15 0.96 1.11 1.55
1.02 0.84 0.86 1.55
0.89 1.20 1.06 1.55
0.91
1.08
0.95
1.17
1.13
0.88
1.10
0.85
1.03
0.95
1.05
1.00
1.52
1.51
1.51
1.50
1.03 1.15 1.18 1.50
1.15 0.88 1.01 1.48
0.98 1.08 1.07 1.47
0.84 1.08 0.91 1.47
1.46 1.50
1.70 1.63
1.37 1.39
1.79 1.71
1.59 1.33
1.38 1.65
1.37
1.63
1.43
1.75
1.56
1.44
1.58
1.50
1.54 1.77
1.70 1.49
1.45 1.57
1.24 1.34
0.94 0.92 0.86 1.46 1.38 1.27
0.93 0.92 0.86 1.46 1.36 1.26
1.07 0.89 0.95 1.45 1.55 1.38
1.03 0.84 0.86 1.44
1.07
0.91
0.99
1.00
0.84
0.97
0.95
1.12
0.90
0.89
0.94
1.11
1.44
1.44
1.44
1.43
1.01 0.92 0.93 1.43
1.49 1.25
1.54
1.31
1.43
1.43
1.3C
1.28
1.35
1.5S
1.45 1.33
rcAA89361 1_s_at AA893611 MX11: MAX interacting protein 1
rcAA799598_at
rc_A1008888_at
rcAA800790_at
rcA1011706_at
rcAA799340_at
AB000778_s_at
rcAA800024_at
U25264_at
rc_Al231292_g_at
rcAA799744_at
M13100cds#2_s_at
AF068860_s_at
rcAA892042_at
X07686cds_s_at
U53475_at
L08814_at
rcAA925556_at
rcAA894101_at
E13732cdsat
AF058791_at
rcAA894345_at
rcAA893195_at
rcAA891222_at
AA799598 Similar to pyruvate dehydrogenase
A1008888 CSTB: cystatin B (stefin B)
AA800790 unknown
A101 1706 similar to SFRS3: splicing factor,
arginine/serine-rich 3
AA799340 TIMP2: tissue inhibitor of metalloproteinase 2
AB000778 PLD1: phospholipase D1, phophatidylcholine-
specific
AA800024 similar to C6orflO9: chromosome 6 open
reading frame 109
U25264 SEPW1: selenoprotein W, 1
A1231292 CST3: cystatin C (amyloid angiopathy and
cerebral hemorrhage)
AA799744 unknown
M13100 Lre3: LINE retrotransposable element 3
AF068860 Defbl: defensin beta 1
AA892042 similar to DDX3X: DEAD (Asp-Glu-Ala-Asp)
box polypeptide 3, X-linked
X07686 RNLB6: Rat Li Rn B6 repetitive DNA element
U53475 LOC51762: RAB-8b protein
L08814
transcription factor/tumor suppressor/cell cycle
mitochondrion/glycolysis/energy production
protease inhibitor
unknown
RNA processing
inhibitor of matrix
metalloproteinases/ECM/cancer
signal transduction/phospholipid
metabolism/Ras signaling/Ca-
signaling/myoblast migration
unknown
oxidoreductase/heart
protease inhibitor
unknown
unknown
immune response
RNA binding/RNA
splicing/translation/development/cell growth/cell
division
unknown
RAS superfamily/GTPase signal transduction
SSRP1: structure specific recognition protein 1 transcription factor
AA925556 similar to CKIP-1: CK2 interacting protein 1;
HQ0024c protein
AA894101 unknown
E13732 CC chemokine receptor
AF058791 G10: maternal G10 transcript
AA894345 PEA15: phosphoprotein enriched in astrocytes
15
AA893195 unknown
AA891222 similar to SS18: synovial sarcoma
translocation, chromosome 18
unknown
unknown
unknown
transcription factor
glucose transport/cell cycle
unknown
cell growth
0.96 0.98 0.94 1.43 1.38
0.95 0.99 0.94 1.42
1.07 1.05 1.12 1.42
0.93 0.96 0.90 1.42
1.15 0.89 1.03 1.42
1.08 0.95 1.03 1.42
1.00 0.99 0.99 1.41
1.13 0.96 1.09 1.41
0.87 0.99 0.86 1.41
0.91 1.01 0.91 1.40
0.84
0.92
0.91
0.97
1.05
1.04
1.09
0.91
0.88
0.96
1.00
0.89
1.39
1.39
1.39
1.38
0.90 1.04 0.94 1.38
0.99 1.07 1.06 1.37
1.00 0.97 0.97 1.36
1.10 0.94 1.04 1.36
1.08 1.08 1.17 1.36
1.00 1.01 1.01 1.36
0.93 1.03 0.96 1.35
1.03 1.00 1.03 1.35
0.99 1.14 1.12 1.34
1.12 0.89 1.00 1.34
1.35 1.33
1.52 1.59
1.32 1.27
1.63 1.45
1.53 1.45
1.41 1.40
1.60 1.53
1.22 1.21
1.27 1.27
1.16
1.28
1.26
1.34
1.22
1.33
1.38
1.22
1.24 1.29
1.35 1.44
1.36 1.32
1.50 1.41
1.46
1.36
1.26
1.39
1.58
1.38
1.30
1.39
1.32 1.50
1.50 1.34
1.341
L12383_at
rcAA892520_g_at
rcAA894099_at
rcAA875225_g.at
D25224_at
L11587_at
rc_A1233749_at
rc_Al169370_at
L38483_at
rcAA800303_at
D21132_at
rc_A1231292_at
rc_Al105448_at
X14323cds_g_at
X69903_at
M86564_at
rc_A1232268_at
X53377cdssat
L12383 ARF4: ADP-ribosylation factor 4
AA892520
AA894099
AA875225
similar to VAT1: vesicle amine transport protein
1 homolog (T californica)
VPS4A: vacuolar protein sorting 4A (yeast)
GNA12: guanine nucleotide binding protein (G
protein), alpha inhibiting activity polypeptide 2
D25224 LAMRI: laminin receptor 1 (ribosomal protein
SA, 67kDa)
Li 1587 PTPRS: protein tyrosine phosphatase, receptor
A1233749
A1169370
L38483
AA800303
D21132
A1231292
A1105448
X14323
X69903
M86564
A1232268
X53377
type, S
RPL30: ribosomal protein L30
TUBA8: tubulin, alpha 8
JAG1: jagged 1 (Alagille syndrome)
RAS superfamily/vesicular trafficking/activator
of phospholipase D/ADP-ribosyltransferase/G
protein GTPase signal transduction
neurotransmitter vesicular transport
intracellular protein trafficking
G protein GTPase signal transduction
cell adhesion to
ECM/differentiation/metastasis/cell surface
receptor signal transduction/ribosome
receptor tyrosine phosphatase/signal
transduction/cell cycle/cell
growth/differentiation/development/cel
adhesion
ribosome
cytoskeleton microtubules
Ca-binding/cell cycle/myoblast
differentiation/hematopoesis/angiogenesis/deve
lopment
similar to PLSCR3: phospholipid scramblase 3 Ca-binding/signal transduction
PITPNB: phosphotidylinositol transfer protein, phospholipid transport
beta
CST3: cystatin C (amyloid angiopathy and protease inhibitor
cerebral hemorrhage)
HSD1 11B1: hydroxysteroid (11-beta) steroid/cortisol metabolism
dehydrogenase 1
FCGRT: Fc fragment of IgG, receptor, immune response/receptor/lgG binding
transporter, alpha
IL4R: interleukin 4 receptor immune response/receptor signal transduction
PTMA: prothymosin, alpha (gene sequence 28) cell cycle/development/transcription
Lrpapl: Low density lipoprotein receptor-related Ca-binding/cell proliferation/receptor/protein
protein associated protein 1 folding/cell cycle/lipoprotein metabolism
Rps7: ribosomal protein S7 ribosome
1.12 0.89 0.99 1.34
1.05
0.94
0.91
1.04
1.00
1.12
1.09
0.94
1.01
1.33
1.33
1.33
0.90 1.04 0.94 1.33
1.49 1.33
1.40
1.25
1.21
1.45
1.25
1.35
1.20 1.25
0.88 1.04 0.91 1.33 1.16 1.21
0.92 1.00 0.92 1.33 1.23 1.23
1.01 0.97 0.98 1.32 1.34 1.30
0.94 1.00 0.94 1.32 1.25 1.24
1.07
0.93
1.04
0.88
0.94
1.01
1.00
1.01
0.87
1.02
1.03
1.19
1.01
0.93
1.09
0.92
0.93
0.95
1.07
1.04
0.95
0.94
1.09
0.93
1.32
1.32
1.32
1.32
1.31
1.31
1.31
1.31
1.17 0.96 1.13 1.30
1.41
1.23
1.36
1.15
1.24
1.33
1.30
1.32
1.23
1.26
1.41
1.37
1.25
1.24
1.42
1.22
1.53 1.47
rc_A1008888_g_at A1008888 CSTB: cystatin B (stefin B) protease inhibitor 1.05 0.98 1.03 1.30 1.36 1.34
rcAA684631_at
rc_A1176170_at
rc_A1177054_at
rc_A1176546_at
L26268_g_at
rcAA859804_at
M94919mRNA f at
X13933_s_at
rcAA875665_g.at
D78613_s_at
rc_A1229655_at
J04187_at
AF020618_g_at
U31463_at
X06483cdsat
rcAA875523_s_at
rcAA946313_s_at
rc_A1176658_s_at
AA684631 unknown
A1176170 FKBP1A: FK506 binding protein 1A, 12kDa
A1177054 RALA: v-ral simian leukemia viral oncogene
homolog A (ras related)
A1176546 HSPCA: heat shock 90kDa protein 1, alpha
L26268 BTG1: B-cell translocation gene 1, anti-
proliferative
AA859804 similar to ElF4EL3: eukaryotic translation
initiation factor 4E-like 3
M94919 beta globin gene
X13933 Calmi: calmodulin 1
AA875665 similar to RCN3: reticulocalbin 3, EF-hand
calcium binding domain
D78613 PTPRE: protein tyrosine phosphatase, receptor
type, E
A1229655 similar to hs CTDSP1: CTD (carboxy-terminal
domain, RNA polymerase 11, polypeptide A)
small phosphatase 1
J04187 Cyp2a2: cytochrome P450, subfamily 2A,
polypeptide 1
AF020618 PPPIR15A: protein phosphatase 1, regulatory
(inhibitor) subunit 15A
U31463 MYH9: myosin, heavy polypeptide 9, non-
muscle
X06483 RPL32: ribosomal protein L32
AA875523 similar to MLC1 SA: myosin light chain 1 slow a
AA946313 SPARC: secreted protein, acidic, cysteine-rich
(osteonectin)
A1176658 HSPB1: heat shock 27kDa protein 1
unknown
immune response/protein folding/interacts with
Ca-release channels important for contraction-
relaxation/signal transduction/cell cycle
signal transduction/Ras family GTPase/cell
cycle/Ca-Calmodulin binding
signal transduction/heat shock protein/protein
folding/cell cycle
tumor suppressor/cell
cycle/angiogenesis/myoblast
differentiation/transcription factor
translation initiation
oxygen transport
Ca-binding/affects K channel voltage gated/G
protein coupled receptor signal
transduction/signaling
Ca-binding/signal transduction
receptor tyrosine phosphatase/signal
transduction/cell growth/differentiation/cell
cycle/activation of K channel voltage gated/Ras
signaling
transcription
steroid metabolism
apoptosis/cell cycle
myosin/cytoskeleton/motor activity/Ca-
Calmodulin binding
ribosome
myosin/Ca-binding/muscle
development/cytoskeleton
Ca-binding/ECM synthesis/cell-shape/cell
cycle/collagen-binding/angiogenesis
heat shock protein/protein folding/cell cycle
iron/copper homeostasis and transport
1.09 1.03 1.12 1.30
1.00 0.99 0.99 1.29
0.96 1.06 1.01 1.29
1.04 1.07 1.11 1.29
1.42 1.46
1.30 1.28
1.24 1.31
1.34 1.44
1.07 0.99 1.06 1.29 1.37 1.36
1.10 0.90 1.00 1.28 1.42 1.28
1.01 1.05 1.06 1.28
1.05 1.09 1.14 1.28
1.29 1.35
1.34 1.46
0.95 1.07 1.02 1.28 1.22 1.30
0.90 1.08 0.97 1.28 1.15 1.24
0.94 1.13 1.06 1.27 1.19 1.35
1.04 0.96 0.99 1.27 1.32 1.27
1.12 0.90 1.01 1.27
1.09 0.89 0.97 1.27
1.02 1.02 1.04 1.27
0.89 1.11 1.00 1.27
1.17 0.98 1.15 1.26
1.17 1.01 1.18 1.26
1.42 1.28
1.38 1.22
1.29 1.32
1.13 1.26
1.48 1.46
1.47 1.49
1.05 1.05 1.10 1.26 1.32 1.3SL33869 Cp: ceruloplasminL33869_at
rc_A1227887_g_at A1227887 CDC42: cell division cycle 42 (GTP binding
rc_A1171085_at
D88666_at
rcAA800017_at
U75929UTR#1_f at
X66369_at
U59184_at
M94918mRNA f at
D29683_at
rc_A1014087_at
M27905_at
U24652_at
rcAl104389_gat
rcAA891729_at
rc_A1228674_s_at
X56325mRNA_s_at
X58200mRNAat
rcAA891828_g_at
M34043_at
rcAA875552_at
rcA1639338_at
M38566mRNA_s_at
A1171085
D88666
AA800017
U75929
X66369
U59184
M94918
D29683
A1014087
M27905
U24652
A1104389
protein, 25kDa)
RPL39: ribosomal protein L39
PLA1A: phospholipase Al member A
unknown
SPARC: secreted protein, acidic, cysteine-rich
(osteonectin)
RPL37: ribosomal protein L37
BAX: BCL2-associated X protein
Hbb: hemoglobin beta chain complex
ECEI: endothelin converting enzyme 1
RPS26: ribosomal protein S26
RPL21: ribosomal protein L21
LNK: lymphocyte adaptor protein
TH: tyrosine hydroxylase
AA891729 RPS27A: ribosomal protein S27a
A1228674 PPIA: peptidylprolyl isomerase A (cyclophilin A)
X56325 Hemoglobin, alpha 1
X58200 RPL23: ribosomal protein L23
AA891828 similar to RAD23A: RAD23 homolog A (S.
cerevisiae)
M34043 Tmsb4x: thymosin beta-4
AA875552
A1639338
M38566
unknown
unknown
CYP27A1: cytochrome P450, family 27,
subfamily A, Dolyveptide 1
morphology/actin polymerization/cytoskeleton
ribosome
phospholipid metabolism
unknown
Ca-binding/ECM synthesis/cell-shape/cell
cycle/collagen-binding/angiogenesis
ribosome
pro-apoptosis/cell cycle/development
oxygen transport
forms endothelin 1/vasoactive/blood
pressure/cell cycle
ribosome
ribosome
immune response/signal transduction
catecholamine biosynthesis rate limiting
enzyme/amino acid metabolism
ribosome
protein folding/immune response/cell cycle
oxygen transport
ribosome
DNA nucleotide excision-repair/ubiquitin
mediated protein degradation
cytoskeleton/immune response/development
unknown
unknown
steroid metabolism/cholesterol homeostasis
0.90 1.07
0.99 1.02
1.10 0.93
1.00 1.11
0.87
1.07
1.08
1.10
1.17
0.90
0.94
1.03
1.15
0.91
1.04
1.05
0.97
1.10
1.06
1.00
0.96
1.01
1.03
1.11
0.99
0.97
1.13
1.16
1.12
0.99
1.00
1.04
1.26
1.25
1.25
1.25
1.25
1.24
1.24
1.24
1.23
1.23
1.23
1.23
1.03 1.04 1.07 1.23
0.96 1.03 0.98 1.22
1.13 1.21
1.24 1.27
1.38 1.28
1.25 1.39
1.08 1.24
1.33 1.20
1.34 1.40
1.36 1.43
1.44 1.39
1.11 1.22
1.16 1.23
1.27 1.27
1.27 1.31
1.17 1.20
0.92 1.10 1.01 1.22 1.12 1.23
1.13 1.01 1.14 1.22 1.37 1.39
0.97 1.04 1.01 1.22 1.18 1.22
1.02 1.10 1.12 1.21 1.24 1.36
1.00 1.01 1.01 1.20 1.20 1.21
1.05 1.03 1.08 1.20 1.26 1.30
1.12 0.91 1.02 1.20 1.35 1.22
signal transduction/cell cycle/cell 1.14 0.91 1.04 1.26 1.43 1.31
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Perl Algorithm 1:
What follows is an algorithm that we wrote using Perl language. The algorithm uses the 4237
array elements defined above as input to isolate SERCA2a target genes. It then clusters these
genes into the 10 transcriptional profiles for SERCA2a targets described in the text (Figure 5).
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# this program is analysislI, it extracts all the genes affected by SERCA
# command line: perl analysis2.txt input.txt >output.txt
# input.txt = dchip.txt
# $FVF is a ratio where FV is the numerator and F the denominator
#enter here immediately below the >1 cutoff, ie 1.5
$hi=1.2;
$1o=1/$hi;
print "\ncutoff:\nHi=$hi\nLow=$o\n\n";
print "This is the list of all the genes AFFECTED BY SERCA2a\n";
while (<>)
{
chomp;
if (/A((. *)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*))$/)
{
$FV F=$7/$6;
$FSFV=$8/$7;
$FSF=$8/$6;
$FNF=$6/$3;
$FS F=$8/$6;
$FSNF=$8/$3;
$FVNF=$7/$3;
unless ((($FSF > $lo) && ($FSF < $hi)) (($FSFV > $lo) && ($FSFV < $hi)))
{$SERCAaffected[$r]="$1"; $r-$r+1;}
}
}
$number- @SERCAaffected;
print "number of genes affected by SERCA is = $number out of 4237 total\n";
print"\nPROBE SET GENE ACCESSION LOCUS LINKNF* NFV NFS* F FV*
FS* FV/F FS/FV FS/F F/NF FV/NF FS/NF prioritycandidate gene probability
for SERCA effect\n\n";
foreach (@SERCAaffected)
{
chomp;
if (/A((.*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*))$/)
{
$FVF=$7/$6;
$FSFV=$8/$7;
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$FS_F=$8/$6;
$FNF=$6/$3;
$FS_F=$8/$6;
$FSNF=$8/$3;
$FVNF=$7/$3;
if (($FVF>$hi && $FSFV>$hi && $FSF>$hi) ($FVF<$lo && $FSFV<$lo &&
$FSF<$lo) 1 ($FVF>$hi && $FSFV<$lo && $FSF<$lo) 11 ($FVF<$lo && $FSFV>$hi
&& $FSF>$hi))
{$probI = 2; $prob2 = "high"; &analysisll;}
if (($FVF>$hi && $FSFV<$lo && $FSF>$hi) ($FVF<$lo && $FSFV>$hi &&
$FSF<$lo))
{$probl = 3; $prob2 = "lower"; &analysislI;}
if (($FVF>$lo && $FVF<$hi && $FSFV>$hi && $FSF>$hi) ($FVF>$lo &&
$FVF<$hi && $FSFV<$lo && $FSF<$o))
{$probl = 1; $prob2 = "highest"; &analysisl;}
}
}
# SUBROUTINE
sub analysislI
{
#setl, 40
if ($FNF>$lo && $FNF<$hi && $FSF>$hi && $FSNF>$hi)
{$setl [$n11="$1 $FVF $FSFV $FSF $FNF $FVNF $FSNF $probl
$prob2"; $nl=$nl+1;}
#set2, 41=mir4O
if ($FNF>$lo && $FNF<$hi && $FSF<$lo && $FSNF<$o)
{$set2[$n2]="$1 $FVF $FSFV $FSF $FNF $FVNF $FSNF $probl
$prob2"; $n2=$n2+1;}
#set3, 46
if ($F NF>$hi && $FSF<$lo && $FSNF>$hi)
{$set3[$n3]="$l $FVF $FSFV $FSF $FNF $FVNF $FSNF $probl
$prob2"; $n3=$n3+1;}
#set4, mir46
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if ($F NF<$lo && $FSF>$hi && $FSNF<$lo)
{$set4[$n4]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n4=$n4+1;}
#set5, 42
if ($F NF>$hi && $FSF<$lo && $FSNF>$lo && $FSNF<$hi)
{$set5[$n5]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n5=$n5+1;}
#set6, 43
if ($F NF<$lo && $FSF>$hi && $FSNF>$lo && $FSNF<$hi)
{$set6[$n6]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n6=$n6+1;}
#set7, 47
if ($FNF>$hi && $FSF<$lo && $FSNF<$lo)
{$set7[$n7]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n7=$n7+1;}
#set8, mir47
if ($FNF<$o && $FSF>$hi && $FSNF>$hi)
{$set8[$n8]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n8=$n8+1;}
#set9, 44
if ($FNF>$hi && $FSF>$hi && $FSNF>$hi)
{$set9[$n9]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n9=$n9+1;}
#setlO, 45=mir44
if ($FNF<$lo && $FSF<$lo && $FSNF<$lo)
{$setlO[$nlO]="$1 $FV_F $FSFV $FS_F
$prob2"; $nlO=$nlO+1;}
$FNF $FVNF
#setl 1, 48
if ($FNF>$lo && $FNF<$hi && $FSF>$hi && $FSNF>$lo &&
{$setll[$nll]="$1 $FV_F $FSFV $FSF $FNF $FVNF
$prob2"; $n11=$nl1+1;}
#setl2, 49=mir48
if ($FNF>$lo && $FNF<$hi && $FSF<$lo && $FSNF>$lo &&
{$setl2[$n12]="$1 $FV_F $FSFV $FSF $FNF $FVNF
$prob2"; $n12=$n12+1;}
}
$FSNF<$hi)
$FSNF
$FSNF<$hi)
$FSNF
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$FSNF
$FSNF
$FSNF
$FSNF
$FSNF
$FSNF
$probl
$probl
$probl
$probl
$probl
$probl
$FSNF $probl
$probl
$probl
#print setI
$numl=@setl;
print "\n\n\nsetl = $numl profile = 40\n";
print "F UNCHANGED from NF, FS UPregulated from F\n\n";
foreach $setl (@setl)
{print "$setl\n"};
#print set2
$num2=@set2;
print "\n\n\nset2 = $num2 profile = 41 = mir4O\n";
print "F UNCHANGED from NF, FS DOWNregulated from F\n\n";
foreach $set2 (@set2)
{print "$set2\n" };
#print set3
$num3=@set3;
print "\n\n\nset3 = $num3
print "F UPregulated from
foreach $set3 (@set3)
{print "$set3\n" };
profile = 46\n";
NF, FS<F but FS>NF\n\n";
#print set4
$num4=@set4;
print "\n\n\nset4 = $num4 profile = mir46\n";
print "F DOWNregulated from NF, FS>F but FS<NF\n\n";
foreach $set4 (@set4)
{print "$set4\n"};
#print set5
$num5=@set5;
print "\n\n\nset5 = $num5 profile = 42\n";
print "F UPregulated from NF, NORMALIZED by SERCA2a\n\n";
foreach $set5 (@set5)
{print "$set5\n" };
#print set6
$num6=@set6;
print "\n\n\nset6 = $num6 profile = 43\n";
print "F DOWNregulated from NF, NORMALIZED by SERCA2a\n\n";
foreach $set6 (@set6)
{print "$set6\n"};
#print set7
$num7=@set7;
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print "\n\n\nset7 = $num7 profile = 47\n";
print "F UPregulated from NF, FS<F and FS<NF\n\n";
foreach $set7 (@set7)
{print "$set7\n"};
#print set8
$num8=@set8;
print "\n\n\nset8 = $num8 profile = mir47\n";
print "F DOWNregulated from NF, FS>F and FS>NF\n\n";
foreach $set8 (@set8)
{print "$set8\n"};
#print set9
$num9=@set9;
print "\n\n\nset9 = $num9 profile = 44\n";
print "F UPregulated from NF, FS UPregulated from F\n\n";
foreach $set9 (@set9)
{print "$set9\n" };
#print set10
$numl 0=@set10;
print "\n\n\nsetlO = $numlO profile =45 = mir44\n";
print "F DOWNregulated from NF, FS DOWNregulated from F\n\n";
foreach $set10 (@set10)
{print "$setlO\n"};
#print set 1
$num 11=@set11;
print "\n\n\nsetl 1 = $numl 1 profile = 48\n";
print "MARGINAL SERCA2a effect: FS UPregulated from F, F=NF\n\n";
foreach $setl 1 (@setl 1)
{print "$set 1\n"};
#print set12
$numl2=@setl2;
print "\n\n\nsetl2 = $numl2 profile =49 =mir48\n";
print "MARGINAL SERCA2a effect: FS DOWNregulated from F, F=NF\n\n";
foreach $setl2 (@setl2)
{print "$setl2\n"};
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Perl Algorithm 2:
What follows is an algorithm that we wrote using Perl language. The algorithm uses the 4237
array elements defined above as input to isolate the genes that are natural adaptive responses to
aortic banding needed for clinical non-failure. It then clusters these genes into the two
transcriptional profiles described in the text (Figure 6).
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# this program is analysisl, it extracts the genes not affected by SERCA
# nor the virus components of its vector
# command line: perl analysis 1.txt input.txt >output.txt
# $FVF is a ratio where FV is the numerator and F the denominator
#enter here immediately below the >1 cutoff, ie 1.5
$hi=1.2;
$lo=1/$hi;
print "\ncutoff:\nHi=$hi\nLow=$o\n\n";
print "This is the list of all the genes NOT AFFECTED BY SERCA2a nor the virus components
of its vector\n";
while (<>)
{
chomp;
if (/A((.*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*))$/){
$FVF=$7/$6;
$FSFV=$8/$7;
$FSF=$8/$6;
$FNF=$6/$3;
$FS F=$8/$6;
$FSNF=$8/$3;
$FVNF=$7/$3;
if ($FSF>$lo && $FSF<$hi)
{$SERCAaffected[$r]="$1"; $r=$r+1;}
}
}
$number= @SERCAaffected;
print "number of genes not affected by SERCA is = $number out of 4237 total\n";
print"\nPROBE SET GENE ACCESSION LOCUS LINKNF* NFV NFS* F FV*
FS* FV/F FS/FV FS/F F/NF FV/NF FS/NF prioritycandidate gene probability
for natural beneficial effect\n\n";
foreach (@SERCAaffected)
{
chomp;
if (/A((.*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*)\t(\d*.\d*))$/)
{
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$FVF=$7/$6;
$FSFV=$8/$7;
$FS_F=$8/$6;
$FNF=$6/$3;
$FS F=$8/$6;
$FSNF=$8/$3;
$FVNF=$7/$3;
# FS=F and FV=F and FS=FV
if (($FVF>$lo && $FVF<$hi) && ($FSFV>$lo && $FSFV<$hi))
{$probl = 1; $prob2 = "highest"; &analysisl;}
# (FS=F and FV=F and FS diff FV) or (FS=F and FS=FV and FV diff F)
if ((($FVF>$lo && $FVF<$hi) && ($FSFV<$lo 11 $FSFV>$hi)) (($FVF<$lo
$FVF>$hi) && ($FSFV>$lo && $FSFV<$hi)))
{$probl = 2; $prob2 = "high"; &analysisl;}
# FS=F and (FV diff F) and (FS diff FV)
if ((($FVF<$lo 11 $FVF>$hi) && ($FSFV<$lo
{$probl = 3; $prob2 = "lower"; &analysisl;}
}}
11 $FSFV>$hi)))
# SUBROUTINE
sub analysisl
{
#setl, 61
if ($FNF<$lo && $FSF>$lo && $FSF<$hi && $FSNF<$o)
{$setl[$nl]="$1 $FV_F $FSFV $FSF $FNF $FVNF
$prob2"; $n1=$nl+1;}
#set2, 63=mir61
if ($F NF>$hi && $FSF>$lo && $FSF<$hi && $FSNF>$hi)
{$set2[$n2]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n2=$n2+1;}
#set3, 62
if ($FNF>$lo && $FNF<$hi && $FSF>$lo && $FSF<$hi &&
$FSNF<$hi)
{$set3[$n3]="$1 $FVF $FSFV $FSF $FNF $FVNF
$prob2"; $n3=$n3+1;}
$FSNF
$FSNF
$FSNF>$lo &&
$FSNF
#set4, 64, 65=mir64, 66, 67=mir66
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$probl
$probl
$probl
if (($FNF>$hi && $FSF>$lo && $FSF<$hi && $FSNF>$lo && $FS NF<$hi) 1
($FNF<$lo && $FSF>$lo && $FSF<$hi && $FSNF>$lo && $FSNF<$hi) ($FNF>$lo
&& $FNF<$hi && $FSF>$lo && $FSF<$hi && $FSNF>$hi) I($FNF>$lo &&
$FNF<$hi && $FSF>$lo && $FSF<$hi && $FSNF<$lo))
{$set4[$n4]="$1 $FVF $FSFV $FSF $FNF $FVNF $FSNF $probl
$prob2"; $n4=$n4+1;}
}
#print setI
$numl=@setl;
print "\n\n\nsetl = $numl profile = 61\n";
print "FS UNCHANGED from F, F DOWNregulated from NF\n\n";
foreach $setl (@setl)
{print "$setl\n"};
#print set2
$num2=@set2;
print "\n\n\nset2 = $num2 profile = 63 = mir6l\n";
print "FS UNCHANGED from F, F UPregulated from NF\n\n";
foreach $set2 (@set2)
{print "$set2\n"};
#print set3
$num3=@set3;
print "\n\n\nset3 = $num3 profile = 62\n";
print "F=NF and FS=F and FS=NF\n\n";
foreach $set3 (@set3)
{print "$set3\n" };
#print set4
$num4=@set4;
print "\n\n\nset4 = $num4 profile = like 62 = 64, 65=mir64, 66, 67-mir66\n";
print "Like 62, -(F=NF and FS=F and FS=NF)\n\n";
foreach $set4 (@set4)
{print "$set4\n"};
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